<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">Front Pediatr</journal-id><journal-id journal-id-type="pmc-domain-id">2282</journal-id><journal-id journal-id-type="pmc-domain">frontpediatrics</journal-id><journal-id journal-id-type="publisher-id">Front. Pediatr.</journal-id><journal-title-group><journal-title>Frontiers in Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2296-2360</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10246753</article-id><article-id pub-id-type="pmcid-ver">PMC10246753.1</article-id><article-id pub-id-type="pmcaid">10246753</article-id><article-id pub-id-type="pmcaiid">10246753</article-id><article-id pub-id-type="pmid">37292372</article-id><article-id pub-id-type="doi">10.3389/fped.2023.1045745</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pediatrics</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Principles of care for pregnant and parenting people with substance use disorder: the obstetrician gynecologist perspective</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Barber</surname><given-names initials="CM">Cecily May</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2111712/overview"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Terplan</surname><given-names initials="M">Mishka</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/424831/overview"/></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label><addr-line>Grayken Center for Addiction</addr-line>, <institution>Boston Medical Center</institution>, <addr-line>Boston, MA</addr-line>, <country>United States</country></aff><aff id="aff2"><label><sup>2</sup></label><addr-line>Department of Obstetrics and Gynecology</addr-line>, <institution>Boston University School of Medicine and Boston Medical Center</institution>, <addr-line>Boston, MA</addr-line>, <country>United States</country></aff><aff id="aff3"><label><sup>3</sup></label><institution>Friends Research Institute</institution>, <addr-line>Baltimore, MD</addr-line>, <country>United States</country></aff><aff id="aff4"><label><sup>4</sup></label><addr-line>Department of Family and Community Medicine</addr-line>, <institution>University of California</institution>, <addr-line>San Francisco, CA</addr-line>, <country>United States</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited by:</bold> Loretta Finnegan, Finnegan Consulting, LLC, United States</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Alison Sally Poulton, The University of Sydney, Australia Jennifer McKinney, Baylor College of Medicine, United States</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Mishka Terplan <email>mterplan@friendsresearch.org</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>5</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>11</volume><issue-id pub-id-type="pmc-issue-id">427660</issue-id><elocation-id>1045745</elocation-id><history><date date-type="received"><day>16</day><month>9</month><year>2022</year></date><date date-type="accepted"><day>17</day><month>4</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>05</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>08</day><month>06</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-01 22:25:14.913"><day>01</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 Terplan and Barber.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Terplan and Barber</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fped-11-1045745.pdf"/><abstract><p>Substance use in pregnant and parenting persons is common, yet still underdiagnosed. Substance use disorder (SUD) is one of the most stigmatized and undertreated chronic medical conditions, and this is exacerbated in the perinatal period. Many providers are not sufficiently trained in screening or treatment for substance use, so gaps in care for this population persist. Punitive policies towards substance use in pregnancy have proliferated, lead to decreased prenatal care, do not improve birth outcomes, and disproportionately impact Black, Indigenous, and other families of color. We discuss the importance of understanding the unique barriers of pregnancy-capable persons and drug overdose as one of the leading causes of maternal death in the United States. We highlight the principles of care from the obstetrician-gynecologist perspective including care for the dyad, person-centered language, and current medical terminology. We then review treatment of the most common substances, discuss SUD during the birthing hospitalization, and highlight the high risk of mortality in the postpartum period.</p></abstract><kwd-group><kwd>addiction</kwd><kwd>pregnancy</kwd><kwd>parenting</kwd><kwd>disparities</kwd><kwd>stigma</kwd></kwd-group><counts><fig-count count="0"/><table-count count="3"/><equation-count count="0"/><ref-count count="147"/><page-count count="0"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Neonatology</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Substance use in pregnant and parenting persons is common, yet both underdiagnosed and undertreated in part due to misunderstanding and misinformation regarding substance use, misuse, and use disorder in pregnancy (<xref rid="B1" ref-type="bibr">1</xref>).</p><p>Most people in the US use drugs (opioids, alcohol, nicotine/tobacco, stimulants, and cannabis) to which some people develop an addiction, including people who are capable of pregnancy (<xref rid="B2" ref-type="bibr">2</xref>). Most people quit or cut back substance use when they become pregnant (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). However, those who continue to use, likely have a substance use disorder (SUD) (<xref rid="B5" ref-type="bibr">5</xref>). Addiction, or SUD, is a chronic and treatable medical condition (<xref rid="B6" ref-type="bibr">6</xref>). Untreated SUD is associated with preterm delivery, low birth weight, and other negative birth outcomes. In contrast, people with treated addiction are more likely to deliver a normal weight infant at term (<xref rid="B7" ref-type="bibr">7</xref>). The old adage &#8220;healthy mother equals healthy baby&#8221; applies to addiction as it does to other chronic diseases in pregnancy.</p><p>Universal assessment of behavioral health is recommended in prenatal care (<xref rid="B8" ref-type="bibr">8</xref>&#8211;<xref rid="B14" ref-type="bibr">14</xref>); however, it is unevenly actualized and some providers and health systems deploy drug testing in place of proper screening (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). Although the effectiveness of treatment in pregnancy is well established, most pregnant people receive no addiction treatment and treatment (including medication) is inequitably distributed across populations (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). In short, the field of addiction medicine as it concerns pregnancy and parenting suffers not from gaps in scientific knowledge, as much as it suffers from gaps in implementation. We know how to care for pregnant and parenting people with SUD. Many of the principles of care were first described almost 50 years ago (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>).</p><p>Pregnancy and postpartum are a period of significant change both biologically and socially and can lead to new or increased contact with healthcare providers. In this role, all providers have an obligation to present information, resources and support that strengthen this family unit. The complexity of the social and historical context in which people who use substances interact with the healthcare system is highlighted during the perinatal period (<xref rid="B21" ref-type="bibr">21</xref>)&#8212;most notably, this population faces unique threats of legal repercussions for reporting use and seeking treatment (<xref rid="B22" ref-type="bibr">22</xref>). This threat and stigma can lead to significant trauma for pregnant and postpartum persons and disproportionately affects non-White families (<xref rid="B23" ref-type="bibr">23</xref>).</p><p>This manuscript reviews the principles of care of pregnant and parenting people with SUD from the obstetrician gynecologist perspective. The authors are both obstetrician gynecologists and addiction medicine providers with combined almost three decades of clinical experience. The discussion is centered on the dyad&#8212;on the indivisible connection between a pregnant person and the fetus (the &#8220;maternal-fetal unit&#8221;) and, following birth, the connection between a new mother and an infant&#8212;and grounded in both foundational texts as well as contemporary data.</p></sec><sec id="s2"><title>Principles and context</title><p>Health care should be both evidence-based and person-centered. Pregnant people with SUD experience discrimination, are denied dignity and respect, and often lack access to evidence-based care (<xref rid="B24" ref-type="bibr">24</xref>). Pregnant people with SUD often have a significant history of trauma, including childhood physical or sexual abuse and current intimate partner violence (<xref rid="B25" ref-type="bibr">25</xref>&#8211;<xref rid="B27" ref-type="bibr">27</xref>). Many have interacted with the child welfare system in the past and the potential of child welfare involvement postpartum looms over the entire perinatal period (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). Finally, the birth experience can be traumatizing which can reaffirm existing medical mistrust (<xref rid="B30" ref-type="bibr">30</xref>).</p><p>To address discrimination and structural inequities, to reflect evidence-based practice, and to actualize person-centered care, attention should focus first on language.</p><p>Language is important. The words we use can convey (intentionally or unintentionally) stigma and prejudice (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). Creating a non-judgmental environment is important to provide appropriate care for persons with substance use disorder. Therefore, providers need to model language that is both evidence-based (i.e., clinically accurate) and person-centered (i.e., non-stigmatizing). Providers should avoid slang and use language that clearly communicates that substance use disorder is a chronic medical condition, that emphasizes treatment (especially medication and behavioral health), and that promotes recovery (see <xref rid="T1" ref-type="table">Table&#160;1</xref>) (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). Finally, it is important to note that &#8220;stigma catches up&#8221; and therefore language that reflects the dignity and humanity of pregnant and parenting people who use drugs is constantly changing. As healthcare professionals, it will be necessary to adapt our terminology as needed.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Addressing stigma by changing the language we use.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Stigmatizing language</td><td valign="top" align="left" rowspan="1" colspan="1">Preferred language</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Addict, junkie, abuser</td><td valign="top" align="left" rowspan="1" colspan="1">Person in active addiction<break/>Person with a substance use disorder<break/>Person in recovery (<xref rid="B1" ref-type="bibr">1</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Addicted baby</td><td valign="top" align="left" rowspan="1" colspan="1">Neonate with in-utero exposure to [substance]<break/>Neonatal abstinence syndrome (<xref rid="B2" ref-type="bibr">2</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Substance abuse</td><td valign="top" align="left" rowspan="1" colspan="1">Substance use or misuse<break/>Substance use disorder</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Clean or sober</td><td valign="top" align="left" rowspan="1" colspan="1">Abstinent<break/>SUD in remission<break/>Testing &#8220;negative&#8221; for [substance]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dirty</td><td valign="top" align="left" rowspan="1" colspan="1">Using [substance]<break/>Testing &#8220;positive&#8221; for [substance] (<xref rid="B3" ref-type="bibr">3</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Replacement or substitution therapy, medication-assisted treatment</td><td valign="top" align="left" rowspan="1" colspan="1">Medication for opioid use disorder (MOUD)<break/>Treatment</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Getting or being high</td><td valign="top" align="left" rowspan="1" colspan="1">Intoxicated<break/>Under the influence of [substance]</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Shooting up</td><td valign="top" align="left" rowspan="1" colspan="1">Intravenous or injection drug use</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Relapse</td><td valign="top" align="left" rowspan="1" colspan="1">Return to use<break/>SUD recurrence</td></tr></tbody></table></table-wrap></sec><sec id="s3"><title>Screening and assessment</title><p>Substance use and use disorder are common&#8212;nearly 1 in 5 pregnant women report any substance (including tobacco, alcohol, or illicit substances) within the past month, and rates of opioids, cannabis, and stimulants in pregnancy have increased in the past decade (<xref rid="B2" ref-type="bibr">2</xref>).</p><p>Universal verbal screening for substance use and misuse using a validated instrument is recommended as a routine part of prenatal care by professional societies and public health agencies (<xref rid="B8" ref-type="bibr">8</xref>&#8211;<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>). In addition, participation in screening is considered voluntary and rests upon the bioethical principle of autonomy and opposition to coercion (see <xref rid="T2" ref-type="table">Table&#160;2</xref>) (<xref rid="B36" ref-type="bibr">36</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>). Hence, it is recommended that providers ask permission prior to screening and recognize the patient's right of refusal if screening is declined. However, universal screening is vastly underutilized and &#8220;risk based&#8221; screening persists&#8212;a practice that operationalizes and perpetuates stigma and with no improvement of diagnostic accuracy (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B39" ref-type="bibr">39</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Tips for addressing mistrust and making clinical care welcoming.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/></colgroup><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Permission for Screening</td><td valign="top" align="left" rowspan="1" colspan="1">Is it ok if I ask you some questions about smoking, drinking and other drugs?</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Prenatal Care and SUD Treatment</td><td valign="top" align="left" rowspan="1" colspan="1">What are you looking for in a provider? What is the most important thing to you about treatment or recovery?</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Medication Decisions</td><td valign="top" align="left" rowspan="1" colspan="1">What do you know about [methadone or buprenorphine]? Do you have any concerns from prior treatment experiences?</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Postpartum Care</td><td valign="top" align="left" rowspan="1" colspan="1">What do I need to know about your birthing experience to help you create an environment to best care for you and your child? What do you need to care for your infant?</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">In General</td><td valign="top" align="left" rowspan="1" colspan="1">What do you need to feel safe?</td></tr></tbody></table></table-wrap><p>There are multiple validated tools to identify problematic substance use including maternal interview and screening questionnaires. Although many screening instruments have been used in pregnancy, only two studies have directly compared the screening instrument performance in pregnancy. Ondersma et al compared 5 instruments: the Substance Use Risk Profile&#8212;Pregnancy (SURP-P), CRAFFT (acronym for five-item screener with items related to car, relax, alone, forget, friends and trouble), 5Ps (parents, peers, partner, pregnancy, past), Wayne Indirect Drug Use Screener (WIDUS), and the National Institute on Drug Abuse (NIDA) Quick Screen (<xref rid="B40" ref-type="bibr">40</xref>). Coleman-Cowger et al compared 3 instruments: 4P's Plus, NIDA Quick Screen-ASSIST, and the SURP-P (<xref rid="B41" ref-type="bibr">41</xref>). No instrument was superior in any of the analyses. Therefore, it is recommended that providers use whatever validated tool is most able to be integrated into the electronic health record.</p><p>Drug <bold>screening</bold> captures behaviors related to substance use. In contrast, drug <bold>testing</bold> is the evaluation of a biological matrix (such as urine, hair, or meconium) for the presence of drug metabolites or parent compounds. Drug testing is not recommended as an appropriate means to identify substance use or misuse, much less addiction (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B36" ref-type="bibr">36</xref>). The information obtained from a drug test is not uniform as the time of detection varies greatly across substances. In addition, both false positive and false negative results are common in drug tests (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). Furthermore, the American Society of Addiction Medicine (ASAM) recommendations are clear that definitive testing (i.e., gas chromatography) is required &#8220;when the results will inform a decision with major clinical or non-clinical implications for the patient&#8221; which, given the realities of child welfare reporting, would be any drug test in pregnancy especially during the birthing hospitalization (<xref rid="B44" ref-type="bibr">44</xref>).</p><p>Screening is not diagnosis, and a positive screen must be followed up with the assessment of DSM criteria for the establishment of diagnosis. Screening helps to stratify patients into risk categories: those that meet criteria for a use disorder need treatment; those with &#8220;moderate risk&#8221; (history of use but without addiction) should receive a brief intervention grounded in motivational interviewing and (more) frequent follow up visits; and those with low risk (no past or current use) should receive brief advice and acknowledgement of their healthy behaviors (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>Although screening is recommended, patients may be legitimately fearful of disclosure, including the threat of legal repercussions (<xref rid="B45" ref-type="bibr">45</xref>). It is important that all providers continue to create a safe and non-judgmental environment that encourages engagement in care. Providers should be honest and transparent regarding how information obtained from either screening or testing is shared with external agencies, including child welfare, and overreporting (use or positive drug testing without protective concerns) should be discouraged.</p></sec><sec id="s4"><title>Treatment</title><p>SUD is a chronic medical condition and like other chronic conditions, outcomes are greatly improved by treatment (<xref rid="B46" ref-type="bibr">46</xref>). There is, however, a large gap in access to treatment (both medication and behavioral) by substance type, with the highest rate of treatment for opioids and the lowest for alcohol (<xref rid="B17" ref-type="bibr">17</xref>). The marked gap in treatment is further magnified by racial inequities. Compared to White individuals, Black and Hispanic populations are less likely to receive any SUD treatment, less likely to receive medication for OUD (MOUD), and if in treatment, receive lower doses of MOUD (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B47" ref-type="bibr">47</xref>).</p><p>Among people with SUD, polysubstance use is common and co-occurring substance use and use disorders can be treated simultaneously. Ideally, care should be delivered in a comprehensive and co-located capacity, that is, through the integration of addiction treatment and prenatal care. Integrated care models have been described since the 1970s, are considered the &#8220;standard of care&#8221;, and are associated with improved birth outcomes (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B20" ref-type="bibr">20</xref>). However, some individuals need a higher level of care. ASAM categorizes addiction treatment along levels of care that range from outpatient to residential and inpatient (<xref rid="B48" ref-type="bibr">48</xref>). Level of care should be evaluated at treatment intake and throughout, especially if treatment is failing a patient at a particular moment. Medication should be available throughout levels of care as should childcare services, although both medication and childcare are often absent and are hence barriers to care for pregnant and parenting people (<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>). In addition, treatment should address concomitant mental health disorders (<xref rid="B51" ref-type="bibr">51</xref>). Below we discuss treatment and outcomes by substance type.</p></sec><sec id="s5"><title>Opioids</title><p>From 1999 to 2014, the rate of OUD complicating birth has increased by more than 4-fold and in some states the rate has increased nearly 10-fold, yet OUD treatment is still stigmatized and underutilized (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B52" ref-type="bibr">52</xref>). Despite public health and professional society recommendations supporting MOUD (<xref rid="B14" ref-type="bibr">14</xref>), pregnant and postpartum individuals with OUD continue to face barriers to treatment, including stigma (<xref rid="B53" ref-type="bibr">53</xref>), discrimination, lack of knowledgeable clinicians (<xref rid="B54" ref-type="bibr">54</xref>), and misinformation about NAS (<xref rid="B55" ref-type="bibr">55</xref>). Available data regarding negative fetal effects of opioids are inconsistent and some of the literature is cross-sectional, retrospective (hence subject to recall and other bias), or outcome assessments are not masked. However, there is no evidence that MOUD (either buprenorphine or methadone) increases risk of congenital anomalies (<xref rid="B56" ref-type="bibr">56</xref>).</p><p>MOUD, including methadone (a full mu-agonist and weak NMDA receptor antagonist), buprenorphine (partial mu-agonist with a high affinity for the mu-opioid receptor and partial mu-antagonist) and naltrexone (nonselective opioid receptor antagonist), save lives and are the standard OUD treatment&#8212;among pregnant and postpartum individuals (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B36" ref-type="bibr">36</xref>). MOUD improve both substance use and pregnancy outcomes and decrease overdose risk compared with no treatment (<xref rid="B57" ref-type="bibr">57</xref>). Evidence for the safety and efficacy of methadone and buprenorphine is the strongest, however due to recent studies confirming safety and efficacy of the buprenorphine-naloxone combination product and persistent barriers to outpatient methadone access in the current flawed system, buprenorphine use is increasing (<xref rid="B58" ref-type="bibr">58</xref>), and a multisite injectable buprenorphine trial in pregnancy is ongoing (<xref rid="B59" ref-type="bibr">59</xref>). Detoxification, or medically supervised withdrawal, is not recommended in pregnancy. Naltrexone is the newest approved MOUD and the least studied in pregnancy; the urgency to close this research gap is currently being addressed in an ongoing multisite trial (<xref rid="B59" ref-type="bibr">59</xref>). Detoxification is not treatment, is associated with return to use and not associated with a decrease in NAS (<xref rid="B60" ref-type="bibr">60</xref>). However, it is important to respect patient autonomy and it may be attempted after shared decision making with counseling on the safety of detoxification and the risk of return to use (<xref rid="B61" ref-type="bibr">61</xref>).</p><p>Although MOUD with either methadone or buprenorphine are the safest and most effective treatment for OUD in pregnancy, most people with OUD receive no treatment in pregnancy (<xref rid="B17" ref-type="bibr">17</xref>), only 50% of people admitted to specialty addiction treatment programs receive medication (<xref rid="B62" ref-type="bibr">62</xref>), and there are marked racial inequities in medication receipt, type, and dose. Black pregnant people are less likely to receive medication compared to White pregnant people and overall, more likely to receive methadone than buprenorphine (<xref rid="B18" ref-type="bibr">18</xref>). Even among those who receive methadone, mean daily doses are highest for White (144.9&#8197;mg) compared to Black (97.5&#8197;mg) pregnant people (<xref rid="B47" ref-type="bibr">47</xref>).</p><p>MOUD dose (methadone or buprenorphine) is not correlated with neonatal abstinence syndrome (<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B64" ref-type="bibr">64</xref>), however there is decreased incidence and severity of NAS associated with buprenorphine compared to methadone (<xref rid="B65" ref-type="bibr">65</xref>). Behavioral interventions, such as contingency management, cognitive behavioral therapy, and family therapy, are helpful (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>) but absence of or non-adherence with behavioral health should not be used as justification to withhold MOUD (<xref rid="B68" ref-type="bibr">68</xref>). Optimal duration of treatment with MOUD is not established and for some individuals may be lifelong, however MOUD discontinuation postpartum is common and is associated with increased rates of return to use, overdose, and death (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B69" ref-type="bibr">69</xref>). Providers should be aware of community resources including peer recovery support services and &#8220;12 step programs&#8221; because use of peer services is associated with increased attendance at OUD medical appointments (<xref rid="B70" ref-type="bibr">70</xref>). Recent qualitative studies suggest that peer services are valued among pregnant and postpartum individuals with OUD and are increasingly accessible through telehealth and online (<xref rid="B71" ref-type="bibr">71</xref>).</p><p>Naloxone (short-acting opioid antagonist) rapidly reverses opioid overdose and is not considered MOUD. Given the increase in intentional and unintentional fentanyl use, pregnant and postpartum individuals and their supports should be counseled on the increased risk of overdose, need for immediate naloxone administration in case of overdose, and to call emergency medical services because multiple doses of naloxone and/or oxygen support may be needed (<xref rid="B72" ref-type="bibr">72</xref>). Because fentanyl is increasing throughout the US and there are increasing reports of xylazine (alpha-2 adrenergic agonist) in the drug supply, further training in overdose prevention and management is needed. Xylazine is sympatholytic causing severe sedation, respiratory depression and slowed heart rate, further complicating overdose prevention and management, therefore provider training is needed on co-prescription of naloxone, education on naloxone-resistant overdoses, and increasing need for respiratory support in xylazine-opioid combination use and patient support training on overdose recognition (<xref rid="B73" ref-type="bibr">73</xref>).</p></sec><sec id="s6"><title>Alcohol</title><p>Binge alcohol use&#8212;4 or more drinks on a single occasion for women&#8212;is common in pregnant individuals in the past month, yet rates of alcohol use and alcohol use disorder (AUD) are likely gravely miscalculated (<xref rid="B2" ref-type="bibr">2</xref>). Although alcohol is an established teratogen and there is no known safe lower limit of alcohol exposure. Fetal alcohol syndrome (FAS) is the leading modifiable cause of intellectual disability and developmental delay in the US, with a similar rate to Down syndrome, and 20 times more common in the US (1.95/1,000) than in Europe (0.08/1,000) (<xref rid="B74" ref-type="bibr">74</xref>). All individuals who report alcohol use should be evaluated for AUD and referred to treatment to avoid withdrawal which can be life-threatening. Untreated withdrawal is associated with a nearly 5% subsequent yearly mortality rate (<xref rid="B75" ref-type="bibr">75</xref>). The American Society of Addiction Medicine recommends initial inpatient management for individuals at risk of severe withdrawal, which includes pregnancy (<xref rid="B76" ref-type="bibr">76</xref>). Withdrawal management alone is not addiction treatment&#8212;the mainstay of treatment for AUD is medication with behavioral interventions because behavioral interventions alone are associated with high rates of return to use (<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>). There are three approved medications for AUD: disulfiram (aldehyde dehydrogenase inhibitor), acamprosate (glutamate/GABA neuromodulator) and naltrexone (mu-opioid receptor antagonist). Due to the exclusion of pregnant individuals from medication trials, there is no evidence base regarding safety and effectiveness in pregnancy (<xref rid="B79" ref-type="bibr">79</xref>), and these medications are vastly underutilized. However, medications for AUD are almost certainly less harmful than untreated AUD and should be considered in the clinical care for pregnant and postpartum individuals (<xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B81" ref-type="bibr">81</xref>).</p></sec><sec id="s7"><title>Nicotine/tobacco</title><p>There is significantly higher tobacco use in individuals who have other SUDs compared to those with no SUD and this does not change dramatically among pregnant and parenting individuals. Although 50% of individuals stop smoking during pregnancy, up to 90% resume within 1 year postpartum (<xref rid="B82" ref-type="bibr">82</xref>). Behavioral interventions, such as cognitive behavioral therapy (CBT) or contingency management, remain the standard treatment for smoking cessation (<xref rid="B83" ref-type="bibr">83</xref>). Nicotine replacement therapy (NRT) has not been shown to be beneficial in smoking cessation in pregnancy, however, NRT can reduce maternal and fetal exposure to nicotine, mitigate maternal lung disease, and reduce second and third-hand smoke exposure postpartum. Although there are limited data on bupropion and varenicline use in pregnancy, a recent analysis suggests safety of bupropion both in pregnancy and breast/chestfeeding (<xref rid="B84" ref-type="bibr">84</xref>). Medications decisions, including NRT, should be individual clinical decisions, balancing risks and benefits, and center on patient autonomy.</p></sec><sec id="s8"><title>Cocaine</title><p>Cocaine use in pregnancy has a shameful history of unscientific and racist rhetoric, filled with false claims of adverse child neurodevelopmental outcomes, teratogenicity, and lifelong mental and physical disability (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B85" ref-type="bibr">85</xref>&#8211;<xref rid="B87" ref-type="bibr">87</xref>). It is important to acknowledge that despite the research disproving these claims, significant stigma persists particularly for Black individuals. Because cocaine can cause hypertensive emergencies and increase myocardial oxygen demand, <italic toggle="yes">in utero</italic> exposure can be associated with preterm birth, placental abruption, preeclampsia-like symptoms, maternal coronary artery vasospasm, and myocardial ischemia, infarction or arrhythmia (<xref rid="B88" ref-type="bibr">88</xref>). A symptom of both the ongoing &#8220;war on drugs&#8221; and the subsequent unequal burden of &#8220;crack&#8221; or crystal cocaine use in Black and poor communities, research on cocaine use disorder (CUD) treatment is limited and there are no medications approved for (CUD) (<xref rid="B89" ref-type="bibr">89</xref>). There is modest evidence for bupropion, topiramate, and psychostimulants, but none of these have been studied in pregnancy (<xref rid="B89" ref-type="bibr">89</xref>). There is increasing evidence that contingency management increases abstinence, and behavioral modalities remain the mainstay of treatment in pregnancy (<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B90" ref-type="bibr">90</xref>).</p></sec><sec id="s9"><title>Methamphetamines</title><p>Methamphetamine is the second most used illicit substance globally and use has been increasing in pregnancy particularly in Western and rural regions of the US (present in 1% of births) and now also in Eastern and urban regions (particularly via injection and not inhalation) (<xref rid="B91" ref-type="bibr">91</xref>). Concurrent opioid and methamphetamine use and methamphetamine-related overdose rates are rapidly increasing globally and this trend is being described as &#8220;a new or fourth wave in the opioid crisis&#8221; (<xref rid="B92" ref-type="bibr">92</xref>). Methamphetamine has vasoconstrictive properties and is associated with preterm birth, low birth weight, and small for gestational age (<xref rid="B93" ref-type="bibr">93</xref>), but it not associated with placental abruption. The IDEAL (Infant Development and Lifestyle) is a prospective multisite cohort study designed to prevent repeating the racism and misleading science of early cocaine research (<xref rid="B94" ref-type="bibr">94</xref>) Results from IDEAL have demonstrated no differences in child development or motor skills at 3 years of age (<xref rid="B95" ref-type="bibr">95</xref>). There are no medications approved for treatment of methamphetamine use disorder (MUD) and none have been studied in pregnancy, however a systematic review of different medications and combinations, demonstrated possible positive effects on treatment outcomes most consistently with stimulant agonists, naltrexone and topiramate (<xref rid="B96" ref-type="bibr">96</xref>). There is also some evidence that mirtazapine results in a small reduction in methamphetamine use, less methamphetamine-positive urine tests, and decreased high risk sexual behaviors, yet it does not increase retention in treatment (<xref rid="B97" ref-type="bibr">97</xref>). Treatment rests primarily contingency management and motivational interviewing (<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B90" ref-type="bibr">90</xref>).</p></sec><sec id="s10"><title>Benzodiazepines</title><p>Benzodiazepines have benefit in the management of acute seizures and alcohol withdrawal, but they do not improve outcomes in the chronic management of depression or anxiety beyond the first month of treatment (<xref rid="B98" ref-type="bibr">98</xref>). Despite this, there are no national guidelines for prescribing and few interventions have been evaluated to reduce benzodiazepine-related problems (<xref rid="B99" ref-type="bibr">99</xref>). Yet benzodiazepines are ubiquitous and play a large role in the overdose crisis in the United States because concurrent use with opioids increases the risk of opioid-related accidental poisoning, particularly in the first 90 days of a new prescription (<xref rid="B100" ref-type="bibr">100</xref>). Benzodiazepines are prescribed more commonly to women as compared to men and may be over prescribed in pregnant and parenting individuals (<xref rid="B101" ref-type="bibr">101</xref>). Benzodiazepines are one of the most frequently prescribed medications in pregnancy: in privately insured individuals, 0.8% have a benzodiazepine prescription (<xref rid="B102" ref-type="bibr">102</xref>). Although concurrent use of benzodiazepines and opioids (including MOUD) is associated with overdose and death, MOUD should be continued despite patient report or detection of benzodiazepine use (<xref rid="B103" ref-type="bibr">103</xref>). Although <italic toggle="yes">in utero</italic> exposure does not suggest teratogenicity or negative effects on neurocognitive development in children, extended <italic toggle="yes">in utero</italic> exposure can cause neonatal withdrawal symptoms similar to opioids and is associated with longer NAS treatment especially in the context of methadone (<xref rid="B104" ref-type="bibr">104</xref>&#8211;<xref rid="B106" ref-type="bibr">106</xref>).</p><p>Similar to alcohol, abrupt cessation of benzodiazepines can be severe and life-threatening. Acute withdrawal is assessed and managed similarly to alcohol withdrawal; however benzodiazepine use disorder (BUD) requires more than withdrawal management and often includes gradual outpatient tapers, which have been shown to have higher efficacy as compared to short-term inpatient care (<xref rid="B107" ref-type="bibr">107</xref>). Effective treatment for BUD includes cognitive behavioral therapy and given the similarities with AUD should include consideration of medications for AUD (<xref rid="B90" ref-type="bibr">90</xref>).</p></sec><sec id="s11"><title>Cannabis</title><p>Cannabis is the most common substance used in the United States that is illegal under federal law. Approximately 5% of pregnant individuals report past-month cannabis use (<xref rid="B2" ref-type="bibr">2</xref>). Many individuals use cannabis to self-treat medical and mental health conditions prior to pregnancy and can continue this use into and during pregnancy especially for pregnancy specific symptoms such as nausea and vomiting (<xref rid="B108" ref-type="bibr">108</xref>, <xref rid="B109" ref-type="bibr">109</xref>). Providers should also be aware of the increasing number of synthetic cannabinoids&#8212;also known as spice or K2&#8212;and of the limited data on maternal and perinatal outcomes (<xref rid="B110" ref-type="bibr">110</xref>). Synthetic cannabinoids have more potent effects than natural cannabinoids including respiratory distress, hypertension, acute renal failure, coagulopathy, psychosis, suicidal ideation, and death (<xref rid="B111" ref-type="bibr">111</xref>). The American College of Obstetricians and Gynecology, the American Academy of Pediatrics, and the US Surgeon General all advise against medical or recreational cannabis during preconception and pregnancy and lactation due to unknown and potential harmful maternal, fetal and child outcomes (<xref rid="B112" ref-type="bibr">112</xref>). Although there are no approved medications for cannabis use disorder, there is some evidence for consideration of <italic toggle="yes">N</italic>-acetylcysteine and gabapentin and there is good evidence for behavioral interventions including motivational enhancements, cognitive behavioral therapy, and contingency management (<xref rid="B113" ref-type="bibr">113</xref>).</p></sec><sec id="s12"><title>The birthing hospitalization</title><p>Prior experiences of discrimination in healthcare settings, concern about pain management, and legitimate fear regarding child welfare intervention make the birthing hospitalization a stressful time for pregnant people with SUD.</p><p>For patients receiving MOUD, the medication should be continued throughout the birthing hospitalization (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B90" ref-type="bibr">90</xref>). Dose verification through medical record review, prescription drug monitoring program, or contact with the opioid treatment program is helpful. MOUD does not provide analgesia, should be considered the patient's &#8220;baseline&#8221;, and people with OUD may require more analgesia compared to people without OUD. Providers discuss options for pain control during prenatal care and upon admission to the birthing hospitalization using a trauma-informed approach founded upon shared decision-making. Some patients may have fears about how opioids analgesia could impact their recovery or may want to avoid opioids altogether, so ascertaining patient preference for pain management is paramount.</p><p>All MOUD (including methadone, buprenorphine, and naltrexone) should be continued including perioperatively for scheduled cesarean delivery to decrease the risk for both return to use and a difficult transition back to MOUD after acute pain has resolved (<xref rid="B114" ref-type="bibr">114</xref>). Existing research confirms better pain control with protocols that account for increased pain sensitivity and higher opioid tolerance in patients with OUD (<xref rid="B115" ref-type="bibr">115</xref>). This approach requires higher doses of short-acting opioids and a multimodal analgesic regimen.</p><p>Labor analgesia should be multi-modal and include topical, regional, and systemic approaches. Short-acting opioids can be safely prescribed and co-used with MOUD, including those on injectable naltrexone. Again, discussion of patient preference and a safety plan for opioids at home is crucial. Some patients may want opioids while in the hospital but may not want to have a prescription on discharge, while others may feel safer with a lock box, additional support, or family involvement. All people who may witness an overdose, including people with OUD and those receiving MOUD, should be co-prescribed naloxone upon hospital discharge (<xref rid="B116" ref-type="bibr">116</xref>, <xref rid="B117" ref-type="bibr">117</xref>).</p><p>The American Academy of Pediatrics state that maternal substance use is &#8220;not a categorical contraindication to breastfeeding&#8221; (<xref rid="B118" ref-type="bibr">118</xref>). Breast or chest feeding is an important nonpharmacologic management of NAS and can be beneficial for all patients in recovery, although sociodemographic characteristics, race, and mental health status are all associated with decreased provider and nursing support of breastfeeding (<xref rid="B119" ref-type="bibr">119</xref>). Due to insufficient data on neurodevelopmental outcomes or risk of vertical infection transmission, breastfeeding in the context of continued illicit substance use is not encouraged. Clinical decisions regarding breastfeeding during the birthing hospitalization, however, must rest on the principles of bioethics including respect for bodily autonomy and adequate support to those who choose to breastfeed should be provided (<xref rid="B118" ref-type="bibr">118</xref>).</p><p>Assessment of behavioral health is an important component of admission and management during the birthing hospitalization. For people who present with untreated substance use disorder, the birthing hospitalization is a critical time to initiate treatment and bridge to continuing care. However, drug testing is grossly overused and misinterpreted despite professional society recommendations against routine drug testing of either the pregnant person or the newborn (<xref rid="B120" ref-type="bibr">120</xref>). A positive drug test result is not evidence of health or ill health, is not listed as a criterion for newborn discharge and is not essential to the diagnosis of NAS (<xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B122" ref-type="bibr">122</xref>). Yet presumptive positive drug test results are often reflexively reported to child welfare. This practice of &#8220;test and report&#8221; which reveals the drug test as not clinical but a primarily moral or parenting test, has been criticized by ACOG: &#8220;The laws, regulations, and policies that require health care practitioners and human service workers to respond to substance use and substance use disorder in a primarily punitive way, require health care providers to function as agents of law enforcement&#8221; (<xref rid="B123" ref-type="bibr">123</xref>). Although rare States mandate drug testing during the birthing hospitalization, Federal legislation is clear. CAPTA (the Child Abuse Prevention and Treatment Act) neither requires testing, nor the reporting of positive test results to child welfare and states unequivocally that substance use is not in-and-of-itself an indication of child abuse. Providers rarely understand the consequences of a report (<xref rid="B124" ref-type="bibr">124</xref>) and operate under the false assumption that an agency of surveillance can provide necessary services to families (<xref rid="B125" ref-type="bibr">125</xref>). Rates of child removal attributed to substance use have doubled in recent years, and the majority of infant reports come from health professionals (<xref rid="B126" ref-type="bibr">126</xref>).</p><p>As previously discussed, for all patients, it is crucial to prescribe naloxone upon discharge, particularly if co-prescribing opioids, but the need for naloxone should be assessed in all patients with OUD. Additionally, many geographic regions increasingly have a contaminated/poisoned illicit drug supply and therefore, there is an increase in unintentional fentanyl exposure. Safety around the&#160;potential for unintentional fentanyl use (i.e., in those with non-opioid SUD) should be addressed and patients with any SUD should be encouraged to have a prescription for or access to naloxone.</p></sec><sec id="s13"><title>Postpartum</title><p>Postpartum is a time of increased vulnerabilities for return to use, SUD recurrence, overdose, and overdose death. Care, which had been focused on the pregnant person, becomes less frequent and shifts from mother to infant and from medical to non-medical domains. Insurance churn, including loss of Medicaid coverage, contributes to care discontinuation especially for addiction treatment (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B127" ref-type="bibr">127</xref>).</p><p>Maternal deaths have been increasing in the US and recent population-based data shows that the peak incidence of self-harm related death (specifically overdose and suicide) is 9&#8211;12 months postpartum (<xref rid="B128" ref-type="bibr">128</xref>&#8211;<xref rid="B131" ref-type="bibr">131</xref>). In contrast to a global trend in reduction of pregnant- and postpartum-related deaths, a large observational study reported a 26% increase in maternal deaths in 48 US states from 2000 to 2014 (<xref rid="B131" ref-type="bibr">131</xref>). Rates of discontinuation of MOUD have been shown to be greater than 50% at 6 months postpartum. Drug deaths are now the leading cause of maternal death in the US (<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B129" ref-type="bibr">129</xref>). Naloxone prescribing and training is essential at delivery hospitalization discharge as is linkage to continuing care.</p><p>High rates of co-occurring mental health and substance use disorders put postpartum persons with SUD at especially high risk of psychiatric morbidity and mortality. Having any substance use disorder or use of illicit substances is associated with at least a threefold greater suicide risk (<xref rid="B132" ref-type="bibr">132</xref>). Additionally, many pregnant persons stop treatment, particularly medications, during pregnancy and do not resume immediately postpartum (<xref rid="B133" ref-type="bibr">133</xref>). Therefore, postpartum persons with SUD should be screened early and repeatedly for anxiety, depression and IPV in the postpartum period and should continue to follow closely with their addiction, obstetric and behavior health providers. Updated in 2018, ACOG recommends screening for depression, anxiety and IPV in all trimesters and the postpartum period and now recommends more and earlier postpartum follow up visits (<xref rid="B134" ref-type="bibr">134</xref>).</p><p>Appropriate continuing care should include postpartum services, Hepatitis C virus (HCV) treatment (if applicable), assessment of risk and discussion of initiation of pre-exposure prophylaxis (PrEP) for HIV, family planning counseling, behavioral health, peer recovery support and a &#8220;warm handoff&#8221; transition to primary care. Providers can partner with community-based organizations, peer support services, home visiting, and Early Head Start to support families and keep people engaged in care. The standard single postpartum visit from the prenatal care provider is likely insufficient for the needs of parenting people with SUD. ACOG recommends redesigning postpartum care to optimize health by focusing on care as an ongoing process with services and support tailored to individual and family needs (<xref rid="B135" ref-type="bibr">135</xref>). Postpartum care includes reproductive life planning and the provision of contraception within a shared decision-making context. Having an SUD is associated with higher rates of unintended pregnancy compared to the general population, especially in the immediate postpartum period (<xref rid="B136" ref-type="bibr">136</xref>)&#8212;86% of persons with SUD did not plan their pregnancy compared to 31%&#8211;47% in the general population (<xref rid="B137" ref-type="bibr">137</xref>). Contraceptive use, particularly the more effective LARC methods, among persons with SUD is lower (<xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B139" ref-type="bibr">139</xref>), however current data suggests that lower uptake of reproductive health services in this population is complex. A recent study found an association between increased postpartum contraceptive use and increased prenatal care visits, OBGYN buprenorphine prescribing and increased postpartum visits (<xref rid="B140" ref-type="bibr">140</xref>). Furthermore, HCV infection is rapidly increasing among reproductive-aged persons with injection drug use (<xref rid="B141" ref-type="bibr">141</xref>) leading to an ACOG recommendation for universal HCV screening in pregnancy (<xref rid="B142" ref-type="bibr">142</xref>). Enhanced engagement in care during pregnancy should not be a missed opportunity to provide persons with OUD access to treatment of other medical disorders such as HCV treatment.</p></sec><sec sec-type="conclusions" id="s14"><title>Conclusion</title><p>Although drug use decreases significantly during pregnancy and continues to decrease from the first to the third trimester, overall substance use&#8212;including opioids, alcohol, cannabis, and cocaine&#8212;is increasing among pregnant people in the US. Substance use trends, treatment access, and child welfare policies differ widely by state and therefore it is important that all providers understand their specific geographic resources and climate. SUD outcomes are significantly improved by treatment, however a large gap in treatment access persists. Among those with need for SUD treatment, only 11% report receiving treatment. Although pregnant people are considered a priority population, structural and racial barriers that exist for all people with SUD persist through pregnancy and worsen postpartum in both access to and adequacy of treatment. Providers for the dyad can serve as another point in the healthcare system at which patients can be appropriately screened and adequately referred to treatment, and therefore should be aware of all resources available to aid in breaking the cycle (see <xref rid="T3" ref-type="table">Table&#160;3</xref>). Although it is established that punitive substance use policies increase adverse perinatal outcomes (<xref rid="B143" ref-type="bibr">143</xref>, <xref rid="B144" ref-type="bibr">144</xref>), the unjust and inhuman separation of the dyad is not widely acknowledged (<xref rid="B145" ref-type="bibr">145</xref>, <xref rid="B146" ref-type="bibr">146</xref>). In short, care should be both evidence-based and person-centered, reflect science and public health but also grounded in human rights, human dignity, and recognize the unique burdens we place on pregnant people, their bodies, and their minds.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Resources for providers.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th valign="top" align="left" colspan="2" rowspan="1">Resources for providers</th><th valign="top" align="center" rowspan="1" colspan="1">Application</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Movement for Family Power</td><td valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.movementforfamilypower.org/" ext-link-type="uri">https://www.movementforfamilypower.org/</ext-link>
</td><td valign="top" align="center" rowspan="1" colspan="1">Advocacy, Legal, Policy</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Drug Policy Alliance</td><td valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://drugpolicy.org/" ext-link-type="uri">https://drugpolicy.org/</ext-link>
</td><td valign="top" align="center" rowspan="1" colspan="1">Advocacy, Legal, Policy</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Academy of Perinatal Harm Reduction</td><td valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.perinatalharmreduction.org/" ext-link-type="uri">https://www.perinatalharmreduction.org/</ext-link>
</td><td valign="top" align="center" rowspan="1" colspan="1">Advocacy, Clinical</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Center on Parenting and Opioids</td><td valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cpo.uoregon.edu/sites/cpo2.uoregon.edu/files/2022-05/substance-use-and-recovery-in-pregnancy-and-early-parenting-full_0.pdf" ext-link-type="uri">https://cpo.uoregon.edu/sites/cpo2.uoregon.edu/files/2022-05/substance-use-and-recovery-in-pregnancy-and-early-parenting-full_0.pdf</ext-link>
</td><td valign="top" align="center" rowspan="1" colspan="1">Clinical. Policy</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SAMHSA</td><td valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://store.samhsa.gov/sites/default/files/d7/priv/sma18-5054.pdf" ext-link-type="uri">https://store.samhsa.gov/sites/default/files/d7/priv/sma18-5054.pdf</ext-link>
</td><td valign="top" align="center" rowspan="1" colspan="1">Clinical, Legal</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NNPQC</td><td valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/reproductivehealth/maternalinfanthealth/nnpqc.htm" ext-link-type="uri">https://www.cdc.gov/reproductivehealth/maternalinfanthealth/nnpqc.htm</ext-link>
</td><td valign="top" align="center" rowspan="1" colspan="1">Clinical</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">National Clinical Consultation Center: Substance Use Warmline</td><td valign="top" align="left" rowspan="1" colspan="1">Substance Use Warmline (855) 300 3595, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nccc.ucsf.edu/clinical-resources/substance-use-resources/" ext-link-type="uri">https://nccc.ucsf.edu/clinical-resources/substance-use-resources/</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">Clinical</td></tr></tbody></table></table-wrap></sec></body><back><sec sec-type="author-contributions" id="s15"><title>Author contributions</title><p>All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p></sec><sec sec-type="COI-statement" id="s16"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s17"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name></person-group>. <article-title>Substance use and use disorder in pregnancy and postpartum</article-title>. <source>Int Rev Psychiatry</source>. (<year>2021</year>) <volume>33</volume>(<issue>6</issue>):<fpage>501</fpage>. <pub-id pub-id-type="doi">10.1080/09540261.2021.1981098</pub-id><pub-id pub-id-type="pmid">34605729</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="other"><collab>Substance Abuse and Mental Health Services Administration</collab>. <comment>Key substance use and mental health indicators in the United States: results from the 2020 national survey on drug use and health, ed. N.S.H.-. HHS Publication No. PEP21-07-01-003. 2021, Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration</comment>.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebrahim</surname><given-names>SH</given-names></name><name name-style="western"><surname>Gfroerer</surname><given-names>J</given-names></name></person-group>. <article-title>Pregnancy-related substance use in the United States during 1996&#8211;1998</article-title>. <source>Obstet Gynecol</source>. (<year>2003</year>) <volume>101</volume>(<issue>2</issue>):<fpage>374</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/s0029-7844(02)02588-7</pub-id><pub-id pub-id-type="pmid">12576263</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peltier</surname><given-names>MR</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>W</given-names></name><name name-style="western"><surname>Verplaetse</surname><given-names>TL</given-names></name><name name-style="western"><surname>Burke</surname><given-names>C</given-names></name><name name-style="western"><surname>Zakiniaeiz</surname><given-names>Y</given-names></name><name name-style="western"><surname>Moore</surname><given-names>K</given-names></name><etal/></person-group><article-title>Licit and illicit drug use across trimesters in pregnant women endorsing past-year substance use: results from national survey on drug use and health (2009&#8211;2019)</article-title>. <source>Arch Womens Ment Health</source>. (<year>2022</year>) <volume>25</volume>(<issue>4</issue>):<fpage>819</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1007/s00737-022-01244-6</pub-id><pub-id pub-id-type="pmid">35737132</pub-id><pub-id pub-id-type="pmcid">PMC9359119</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>CE</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Krans</surname><given-names>EE</given-names></name></person-group>. <article-title>Pain, opioids, and pregnancy: historical context and medical management</article-title>. <source>Clin Perinatol</source>. (<year>2019</year>) <volume>46</volume>(<issue>4</issue>):<fpage>833</fpage>&#8211;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.clp.2019.08.013</pub-id><pub-id pub-id-type="pmid">31653311</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="other"><collab>Medicine, A.S.o.A</collab>. <comment>Definition of addiction. 2019. Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.asam.org/quality-care/definition-of-addiction" ext-link-type="uri">https://www.asam.org/quality-care/definition-of-addiction</ext-link><comment>(Accessed September 15, 2022)</comment>.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotelchuck</surname><given-names>M</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>ER</given-names></name><name name-style="western"><surname>Belanoff</surname><given-names>C</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Babakhanlou-Chase</surname><given-names>H</given-names></name><name name-style="western"><surname>Derrington</surname><given-names>TM</given-names></name><etal/></person-group><article-title>The prevalence and impact of substance use disorder and treatment on maternal obstetric experiences and birth outcomes among singleton deliveries in Massachusetts</article-title>. <source>Matern Child Health J</source>. (<year>2017</year>) <volume>21</volume>(<issue>4</issue>):<fpage>893</fpage>&#8211;<lpage>902</lpage>. <pub-id pub-id-type="doi">10.1007/s10995-016-2190-y</pub-id><pub-id pub-id-type="pmid">27832443</pub-id><pub-id pub-id-type="pmcid">PMC5380534</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><article-title>Committee opinion No. 711: opioid use and opioid use disorder in pregnancy</article-title>. <source>Obstet Gynecol</source>. (<year>2017</year>) <volume>130</volume>(<issue>2</issue>):<fpage>e81</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000002235</pub-id><pub-id pub-id-type="pmid">28742676</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patrick</surname><given-names>SW</given-names></name><name name-style="western"><surname>Schiff</surname><given-names>DM</given-names></name></person-group>. <article-title>A public health response to opioid use in pregnancy</article-title>. <source>Pediatrics</source>. (<year>2017</year>) <volume>139</volume>(<issue>3</issue>):<fpage>e20164070</fpage>. <pub-id pub-id-type="doi">10.1542/peds.2016-4070</pub-id><pub-id pub-id-type="pmid">28219965</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ecker</surname><given-names>J</given-names></name><name name-style="western"><surname>Abuhamad</surname><given-names>A</given-names></name><name name-style="western"><surname>Hill</surname><given-names>W</given-names></name><name name-style="western"><surname>Bailit</surname><given-names>J</given-names></name><name name-style="western"><surname>Bateman</surname><given-names>BT</given-names></name><name name-style="western"><surname>Berghella</surname><given-names>V</given-names></name><etal/></person-group><article-title>Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the society for maternal-fetal medicine, American college of obstetricians and gynecologists, and American society of addiction medicine</article-title>. <source>Am J Obstet Gynecol</source>. (<year>2019</year>) <volume>221</volume>(<issue>1</issue>):<fpage>B5</fpage>&#8211;<lpage>B28</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajog.2019.03.022</pub-id><pub-id pub-id-type="pmid">30928567</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>TE</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Ondersma</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Yonkers</surname><given-names>K</given-names></name><name name-style="western"><surname>Chang</surname><given-names>G</given-names></name><name name-style="western"><surname>Creanga</surname><given-names>AA</given-names></name><etal/></person-group><article-title>The role of screening, brief intervention, and referral to treatment in the perinatal period</article-title>. <source>Am J Obstet Gynecol</source>. (<year>2016</year>) <volume>215</volume>(<issue>5</issue>):<fpage>539</fpage>&#8211;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajog.2016.06.038</pub-id><pub-id pub-id-type="pmid">27373599</pub-id><pub-id pub-id-type="pmcid">PMC11362984</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>S</given-names></name><name name-style="western"><surname>Ordean</surname><given-names>A</given-names></name><name name-style="western"><surname>Kahan</surname><given-names>M</given-names></name></person-group>. <article-title>Substance use in pregnancy</article-title>. <source>J Obstet Gynaecol Can</source>. (<year>2011</year>) <volume>33</volume>(<issue>4</issue>):<fpage>367</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/S1701-2163(16)34855-1</pub-id><pub-id pub-id-type="pmid">21501542</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klaman</surname><given-names>SL</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>K</given-names></name><name name-style="western"><surname>Leopold</surname><given-names>A</given-names></name><name name-style="western"><surname>Perpich</surname><given-names>J</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>S</given-names></name><name name-style="western"><surname>Vender</surname><given-names>J</given-names></name></person-group>. <article-title>Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance</article-title>. <source>J Addict Med</source>. (<year>2017</year>) <volume>11</volume>(<issue>3</issue>):<fpage>178</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1097/ADM.0000000000000308</pub-id><pub-id pub-id-type="pmid">28406856</pub-id><pub-id pub-id-type="pmcid">PMC5457836</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>UM</given-names></name><name name-style="western"><surname>Davis</surname><given-names>JM</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Z</given-names></name><name name-style="western"><surname>Greene</surname><given-names>MF</given-names></name></person-group>; <comment>Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes Workshop Invited Speakers</comment>. <article-title>Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes: executive summary of a joint workshop by the eunice kennedy shriver national institute of child health and human development, American college of obstetricians and gynecologists, American academy of pediatrics, society for maternal-fetal medicine, centers for disease control and prevention, and the march of dimes foundation</article-title>. <source>Obstet Gynecol</source>. (<year>2017</year>) <volume>130</volume>(<issue>1</issue>):<fpage>10</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000002054</pub-id><pub-id pub-id-type="pmid">28594753</pub-id><pub-id pub-id-type="pmcid">PMC5486414</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>JY</given-names></name><name name-style="western"><surname>Tong</surname><given-names>VT</given-names></name><name name-style="western"><surname>Haight</surname><given-names>SC</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Stark</surname><given-names>L</given-names></name><name name-style="western"><surname>Snead</surname><given-names>C</given-names></name><etal/></person-group><article-title>Obstetrician&#8211;gynecologists&#8217; practices and attitudes on substance use screening during pregnancy</article-title>. <source>J Perinatol</source>. (<year>2020</year>) <volume>40</volume>(<issue>3</issue>):<fpage>422</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1038/s41372-019-0542-3</pub-id><pub-id pub-id-type="pmid">31666646</pub-id><pub-id pub-id-type="pmcid">PMC7047638</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koy</surname><given-names>JY</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>T</given-names></name><name name-style="western"><surname>Hoeppner</surname><given-names>BB</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>W</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>H</given-names></name><name name-style="western"><surname>Bernson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Obstetrician&#8211;gynecologists&#8217; practice patterns related to opioid use during pregnancy and postpartum&#8212;United States, 2017</article-title>. <source>J Perinatol</source>. (<year>2020</year>) <volume>40</volume>(<issue>3</issue>):<fpage>412</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1038/s41372-019-0535-2</pub-id><pub-id pub-id-type="pmid">31616051</pub-id><pub-id pub-id-type="pmcid">PMC7047516</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>CE</given-names></name><name name-style="western"><surname>Scialli</surname><given-names>A</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name></person-group>. <article-title>Unmet substance use disorder treatment need among reproductive age women</article-title>. <source>Drug Alcohol Depend</source>. (<year>2020</year>) <volume>206</volume>:<fpage>107679</fpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2019.107679</pub-id><pub-id pub-id-type="pmid">31740208</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiff</surname><given-names>DM</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>T</given-names></name><name name-style="western"><surname>Hoeppner</surname><given-names>BB</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>W</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>H</given-names></name><name name-style="western"><surname>Bernson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in Massachusetts</article-title>. <source>JAMA Network Open</source>. (<year>2020</year>) <volume>3</volume>(<issue>5</issue>):<fpage>e205734</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.5734</pub-id><pub-id pub-id-type="pmid">32453384</pub-id><pub-id pub-id-type="pmcid">PMC7251447</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Connaughton</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Finnegan</surname><given-names>LP</given-names></name><name name-style="western"><surname>Schut</surname><given-names>J</given-names></name><name name-style="western"><surname>Emich</surname><given-names>JP</given-names></name></person-group>. <article-title>Current concepts in the management of the pregnant opiate addict</article-title>. <source>Addict Dis</source>. (<year>1975</year>) <volume>2</volume>(<issue>1-2</issue>):<fpage>21</fpage>&#8211;<lpage>35</lpage>. PMID: <pub-id pub-id-type="pmid">1163364</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finnegan</surname><given-names>LP</given-names></name></person-group>. <article-title>Management of pregnant drug-dependent women</article-title>. <source>Ann N Y Acad Sci</source>. (<year>1978</year>) <volume>311</volume>:<fpage>135</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.1978.tb16770.x</pub-id><pub-id pub-id-type="pmid">283714</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name></person-group>. <article-title>Women and the opioid crisis: historical context and public health solutions</article-title>. <source>Fertil Steril</source>. (<year>2017</year>) <volume>108</volume>(<issue>2</issue>):<fpage>195</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2017.06.007</pub-id><pub-id pub-id-type="pmid">28697909</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wakeman</surname><given-names>SE</given-names></name><name name-style="western"><surname>Bryant</surname><given-names>A</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>N</given-names></name></person-group>. <article-title>Redefining child protection: addressing the Harms of structural racism and punitive approaches for birthing people, dyads, and families affected by substance use</article-title>. <source>Obstet Gynecol</source>. (<year>2022</year>) <volume>140</volume>(<issue>2</issue>):<fpage>167</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000004786</pub-id><pub-id pub-id-type="pmid">35852265</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguemeni Tiako</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>L</given-names></name></person-group>. <article-title>The government's involvement in prenatal drug testing may be toxic</article-title>. <source>Matern Child Health J</source>. (<year>2022</year>) <volume>26</volume>(<issue>4</issue>):<fpage>761</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1007/s10995-020-03110-2</pub-id><pub-id pub-id-type="pmid">33392931</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Goodwin</surname><given-names>M</given-names></name></person-group>. <source>Policing the womb: Invisible women and the criminalization of motherhood</source>. <publisher-name>Cambridge University Press</publisher-name> (<year>2020</year>).</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kors</surname><given-names>S</given-names></name><name name-style="western"><surname>Kurdziel-Adams</surname><given-names>G</given-names></name><name name-style="western"><surname>Towers</surname><given-names>C</given-names></name><name name-style="western"><surname>Fortner</surname><given-names>K</given-names></name><name name-style="western"><surname>Macfie</surname><given-names>J</given-names></name></person-group>. <article-title>Sexual abuse as a risk factor for opioid misuse in pregnancy</article-title>. <source>J Child Sex Abus</source>. (<year>2022</year>) <volume>31</volume>(<issue>5</issue>):<fpage>538</fpage>&#8211;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1080/10538712.2022.2056104</pub-id><pub-id pub-id-type="pmid">35395922</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torchalla</surname><given-names>I</given-names></name><name name-style="western"><surname>Linden</surname><given-names>IA</given-names></name><name name-style="western"><surname>Strehlau</surname><given-names>V</given-names></name><name name-style="western"><surname>Neilson</surname><given-names>EK</given-names></name><name name-style="western"><surname>Krausz</surname><given-names>M</given-names></name></person-group>. <article-title>&#8220;Like a lots happened with my whole childhood&#8221;: violence, trauma, and addiction in pregnant and postpartum women from Vancouver's downtown eastside</article-title>. <source>Harm Reduct J</source>. (<year>2015</year>) <volume>11</volume>:<fpage>34</fpage>. <pub-id pub-id-type="doi">10.1186/1477-7517-11-34</pub-id><pub-id pub-id-type="pmid">25928082</pub-id><pub-id pub-id-type="pmcid">PMC4351972</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanjuan</surname><given-names>PM</given-names></name><name name-style="western"><surname>Pearson</surname><given-names>MR</given-names></name><name name-style="western"><surname>Fokas</surname><given-names>K</given-names></name><name name-style="western"><surname>Leeman</surname><given-names>LM</given-names></name></person-group>. <article-title>A mother's bond: an ecological momentary assessment study of posttraumatic stress disorder symptoms and substance craving during pregnancy</article-title>. <source>Psychol Addict Behav</source>. (<year>2020</year>) <volume>34</volume>(<issue>2</issue>):<fpage>269</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1037/adb0000543</pub-id><pub-id pub-id-type="pmid">31829665</pub-id><pub-id pub-id-type="pmcid">PMC7064398</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leiner</surname><given-names>C</given-names></name><name name-style="western"><surname>Cody</surname><given-names>T</given-names></name><name name-style="western"><surname>Mullins</surname><given-names>N</given-names></name><name name-style="western"><surname>Ramage</surname><given-names>M</given-names></name><name name-style="western"><surname>Ostrach</surname><given-names>BMM</given-names></name></person-group>. <article-title>&#8220;The elephant in the room;&#8221; a qualitative study of perinatal fears in opioid use disorder treatment in southern appalachia</article-title>. <source>BMC Pregnancy Childbirth</source>. (<year>2021</year>) <volume>21</volume>(<issue>1</issue>):<fpage>143</fpage>. <pub-id pub-id-type="doi">10.1186/s12884-021-03596-w</pub-id><pub-id pub-id-type="pmid">33596843</pub-id><pub-id pub-id-type="pmcid">PMC7890815</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paris</surname><given-names>R</given-names></name><name name-style="western"><surname>Herriott</surname><given-names>AL</given-names></name><name name-style="western"><surname>Maru</surname><given-names>M</given-names></name><name name-style="western"><surname>Hackign</surname><given-names>SE</given-names></name><name name-style="western"><surname>Sommer</surname><given-names>AR</given-names></name></person-group>. <article-title>Secrecy versus disclosure: women with substance use disorders share experiences in help seeking during pregnancy</article-title>. <source>Matern Child Health J</source>. (<year>2020</year>) <volume>24</volume>(<issue>11</issue>):<fpage>1396</fpage>&#8211;<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1007/s10995-020-03006-1</pub-id><pub-id pub-id-type="pmid">33025236</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berman</surname><given-names>H</given-names></name><name name-style="western"><surname>Mason</surname><given-names>R</given-names></name><name name-style="western"><surname>Hall</surname><given-names>J</given-names></name><name name-style="western"><surname>Rodger</surname><given-names>S</given-names></name><name name-style="western"><surname>Classen</surname><given-names>CC</given-names></name><name name-style="western"><surname>Evans</surname><given-names>MK</given-names></name><name name-style="western"><surname>Ross</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Laboring to mother in the context of past trauma: the transition to motherhood</article-title>. <source>Qual Health Res</source>. (<year>2014</year>) <volume>24</volume>(<issue>9</issue>):<fpage>1253</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1177/1049732314521902</pub-id><pub-id pub-id-type="pmid">24501114</pub-id><pub-id pub-id-type="pmcid">PMC4232343</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiff</surname><given-names>DM</given-names></name><name name-style="western"><surname>Halvorson</surname><given-names>AE</given-names></name><name name-style="western"><surname>Dupont</surname><given-names>W</given-names></name><name name-style="western"><surname>Davis</surname><given-names>MM</given-names></name><name name-style="western"><surname>Patrick</surname><given-names>SW</given-names></name></person-group>. <article-title>Impact of stigmatizing language describing opioid-exposed mother infant dyads: a randomized case vignette study</article-title>. <source>Subst Abus</source>. (<year>2022</year>) <volume>43</volume>(<issue>1</issue>):<fpage>551</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1080/08897077.2021.1975866</pub-id><pub-id pub-id-type="pmid">34586979</pub-id><pub-id pub-id-type="pmcid">PMC9644408</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiff</surname><given-names>DM</given-names></name><name name-style="western"><surname>Stoltman</surname><given-names>JJK</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>T</given-names></name><name name-style="western"><surname>Myers</surname><given-names>S</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>M</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Assessing stigma towards substance use in pregnancy: a randomized study testing the impact of stigmatizing language and type of opioid use on attitudes toward mothers with opioid use disorder</article-title>. <source>J Addict Med</source>. (<year>2022</year>) <volume>16</volume>(<issue>1</issue>):<fpage>77</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1097/ADM.0000000000000832</pub-id><pub-id pub-id-type="pmid">33758119</pub-id><pub-id pub-id-type="pmcid">PMC8443692</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atayde</surname><given-names>AMP</given-names></name><name name-style="western"><surname>Hauc</surname><given-names>SC</given-names></name><name name-style="western"><surname>Bessette</surname><given-names>LG</given-names></name><name name-style="western"><surname>Danckers</surname><given-names>H</given-names></name><name name-style="western"><surname>Saitz</surname><given-names>R</given-names></name></person-group>. <article-title>Changing the narrative: A call to end stigmatizing terminology related to substance use disorders</article-title>. <source>Addict Res Theory</source>. <volume>29</volume>(<issue>5</issue>):<fpage>1</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1080/16066359.2021.1875215</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saitz</surname><given-names>R</given-names></name></person-group>. <article-title>International statement recommending against the use of terminology that can stigmatize people</article-title>. <source>J Addict Med</source>. (<year>2016</year>) <volume>10</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1097/ADM.0000000000000178</pub-id><pub-id pub-id-type="pmid">26588846</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="other"><collab>Medicine, A.S.o.A</collab>. <comment>Substance use and substance use disorder among pregnant and postpartum people (2022). Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.asam.org/advocacy/public-policy-statements/details/public-policy-statements/2022/10/12/substance-use-and-substance-use-disorder-among-pregnant-and-postpartum-people" ext-link-type="uri">https://www.asam.org/advocacy/public-policy-statements/details/public-policy-statements/2022/10/12/substance-use-and-substance-use-disorder-among-pregnant-and-postpartum-people</ext-link><comment>(Accessed January 11, 2023)</comment>.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="book"><collab>Administration, S.A.a.M.H.S.</collab><source>Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants, ed. H.P.N.S. 18-5054</source>. <publisher-loc>Rockville, MD</publisher-loc>: <publisher-name>Substance Abuse and Mental Health Services Administration</publisher-name> (<year>2018</year>).</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><article-title>Committee opinion 664: refusal of medically recommended treatment during pregnancy</article-title>. <source>Obstet Gynecol</source>, <year>2016</year>. <volume>127</volume>:<fpage>e175</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000001485</pub-id><pub-id pub-id-type="pmid">27214192</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="other"><collab>Association, A.M</collab>. <comment>Legal interventions during pregnancy. Policy statement H-420.969 (2018). Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://policysearch.ama-assn.org/policyfinder/detail/women?uri=%2FAMADoc%2FHOD.xml-0-3712.xml" ext-link-type="uri">https://policysearch.ama-assn.org/policyfinder/detail/women?uri=%2FAMADoc%2FHOD.xml-0-3712.xml</ext-link><comment>(Accessed September 15, 2022)</comment>.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerker</surname><given-names>BD</given-names></name><name name-style="western"><surname>Horwitz</surname><given-names>SM</given-names></name><name name-style="western"><surname>Leventhal</surname><given-names>JM</given-names></name></person-group>. <article-title>Patients&#8217; characteristics and providers&#8217; attitudes: predictors of screening pregnant women for illicit substance use</article-title>. <source>Child Abuse Negl</source>. (<year>2004</year>) <volume>28</volume>(<issue>2</issue>):<fpage>209</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.chiabu.2003.07.004</pub-id><pub-id pub-id-type="pmid">15003403</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ondersma</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Chang</surname><given-names>G</given-names></name><name name-style="western"><surname>Blake-Lamb</surname><given-names>T</given-names></name><name name-style="western"><surname>Gilstad-Hayden</surname><given-names>K</given-names></name><name name-style="western"><surname>Orav</surname><given-names>J</given-names></name><name name-style="western"><surname>Beatty</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Accuracy of five self-report screening instruments for substance use in pregnancy</article-title>. <source>Addiction</source>. (<year>2019</year>) <volume>114</volume>(<issue>9</issue>):<fpage>1683</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1111/add.14651</pub-id><pub-id pub-id-type="pmid">31216102</pub-id><pub-id pub-id-type="pmcid">PMC8407406</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coleman-Cowger</surname><given-names>V</given-names></name><name name-style="western"><surname>Oga</surname><given-names>EA</given-names></name><name name-style="western"><surname>Peters</surname><given-names>EN</given-names></name><name name-style="western"><surname>Trocin</surname><given-names>KE</given-names></name><name name-style="western"><surname>Koszowski</surname><given-names>B</given-names></name><name name-style="western"><surname>Mark</surname><given-names>K</given-names></name></person-group>. <article-title>Accuracy of three screening tools for prenatal substance use</article-title>. <source>Obstet Gynecol</source>. (<year>2019</year>) <volume>133</volume>(<issue>5</issue>):<fpage>952</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000003230</pub-id><pub-id pub-id-type="pmid">30969217</pub-id><pub-id pub-id-type="pmcid">PMC6485306</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wanar</surname><given-names>A</given-names></name><name name-style="western"><surname>Isley</surname><given-names>BC</given-names></name><name name-style="western"><surname>Saia</surname><given-names>K</given-names></name><name name-style="western"><surname>Field</surname><given-names>TA</given-names></name></person-group>. <article-title>False-positive fentanyl urine detection after initiation of labetalol treatment for hypertension in pregnancy: a case report</article-title>. <source>J Addict Med</source>. (<year>2012</year>) <volume>16</volume>(<issue>6</issue>):<fpage>e417</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/ADM.0000000000001010</pub-id><pub-id pub-id-type="pmid">35972891</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yee</surname><given-names>LM</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name></person-group>. <article-title>False-positive amphetamine toxicology screen results in three pregnant women using labetalol</article-title>. <source>Obstet Gynecol</source>. (<year>2011</year>) <volume>117</volume>(<issue>Part 2</issue>):<fpage>503</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0b013e318206c07c</pub-id><pub-id pub-id-type="pmid">21252805</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jarvis</surname><given-names>M</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J</given-names></name><name name-style="western"><surname>Hurford</surname><given-names>M</given-names></name><name name-style="western"><surname>Lindsay</surname><given-names>D</given-names></name><name name-style="western"><surname>Lincoln</surname><given-names>P</given-names></name><name name-style="western"><surname>Giles</surname><given-names>L</given-names></name><etal/></person-group><article-title>Appropriate use of drug testing in clinical addiction medicine</article-title>. <source>J Addict Med</source>. (<year>2017</year>) <volume>11</volume>(<issue>3</issue>):<fpage>163</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1097/ADM.0000000000000323</pub-id><pub-id pub-id-type="pmid">28557958</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stone</surname><given-names>R</given-names></name></person-group>. <article-title>Pregnant women and substance use: fear, stigma, and barriers to care</article-title>. <source>Health Justice</source>. (<year>2015</year>) <volume>3</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1186/s40352-015-0015-5</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLellan</surname><given-names>AT</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>DC</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>CP</given-names></name><name name-style="western"><surname>Kleber</surname><given-names>HD</given-names></name></person-group>. <article-title>Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation</article-title>. <source>J Am Med Assoc</source>. (<year>2000</year>) <volume>284</volume>(<issue>13</issue>):<fpage>1689</fpage>&#8211;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1001/jama.284.13.1689</pub-id><pub-id pub-id-type="pmid">11015800</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenthal</surname><given-names>EW</given-names></name><name name-style="western"><surname>Short</surname><given-names>VL</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>Y</given-names></name><name name-style="western"><surname>Barber</surname><given-names>C</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>JK</given-names></name><name name-style="western"><surname>Abatemarco</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Racial inequity in methadone dose at delivery in pregnant women with opioid use disorder</article-title>. <source>J Subst Abuse Treat</source>. (<year>2021</year>) <volume>131</volume>:<fpage>108454</fpage>. <pub-id pub-id-type="doi">10.1016/j.jsat.2021.108454</pub-id><pub-id pub-id-type="pmid">34098304</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gastfriend</surname><given-names>DR</given-names></name><name name-style="western"><surname>Mee-Lee</surname><given-names>D</given-names></name></person-group>. <article-title>Thirty years of TheASAMCriteria: a report card</article-title>. <source>Psychiatr Clin North Am</source>. (<year>2022</year>) <volume>45</volume>(<issue>3</issue>):<fpage>593</fpage>&#8211;<lpage>609</lpage>. <pub-id pub-id-type="doi">10.1016/j.psc.2022.05.008</pub-id><pub-id pub-id-type="pmid">36055741</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madras</surname><given-names>BK</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Wen</surname><given-names>J</given-names></name><name name-style="western"><surname>Sharfstein</surname><given-names>JS</given-names></name></person-group>. <article-title>Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system</article-title>. <source>NAM Perspect</source>. (<year>2020</year>) <volume>2020</volume>. <pub-id pub-id-type="doi">10.31478/202004b</pub-id><pub-id pub-id-type="pmid">35291732</pub-id><pub-id pub-id-type="pmcid">PMC8916813</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Longinaker</surname><given-names>N</given-names></name><name name-style="western"><surname>Appel</surname><given-names>L</given-names></name></person-group>. <article-title>Women-centered drug treatment services and need in the United States, 2002-2009</article-title>. <source>Am J Public Health</source>. (<year>2015</year>) <volume>105</volume>(<issue>11</issue>):<fpage>e50</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.2105/AJPH.2015.302821</pub-id><pub-id pub-id-type="pmid">26378825</pub-id><pub-id pub-id-type="pmcid">PMC4605167</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>HW</given-names></name></person-group>. <article-title>Residential substance abuse treatment for pregnant and postpartum women and their children: treatment and policy implications</article-title>. <source>Child Welfare</source>. (<year>2001</year>) <volume>80</volume>(<issue>2</issue>):<fpage>179</fpage>&#8211;<lpage>98</lpage>. PMID: <pub-id pub-id-type="pmid">11291900</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haight</surname><given-names>SC</given-names></name><name name-style="western"><surname>Ko</surname><given-names>JY</given-names></name><name name-style="western"><surname>Tong</surname><given-names>VT</given-names></name><name name-style="western"><surname>Bohm</surname><given-names>MK</given-names></name><name name-style="western"><surname>Callaghan</surname><given-names>WM</given-names></name></person-group>. <article-title>Opioid use disorder documented at delivery hospitalization - United States, 1999-2014</article-title>. <source>Morb Mortal Wkly Rep</source>. (<year>2018</year>) <volume>67</volume>(<issue>31</issue>):<fpage>845</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm6731a1</pub-id><pub-id pub-id-type="pmcid">PMC6089335</pub-id><pub-id pub-id-type="pmid">30091969</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Kennedy-Hendricks</surname><given-names>A</given-names></name><name name-style="western"><surname>Chisolm</surname><given-names>MS</given-names></name></person-group>. <article-title>Prenatal substance use: exploring assumptions of maternal unfitness</article-title>. <source>Subst Abuse</source>. (<year>2015</year>) <volume>9</volume>(<issue>Suppl 2</issue>):<fpage>1</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.4137/SART.S23328</pub-id><pub-id pub-id-type="pmid">26448685</pub-id><pub-id pub-id-type="pmcid">PMC4578572</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clearly</surname><given-names>EM</given-names></name><name name-style="western"><surname>Smid</surname><given-names>MC</given-names></name><name name-style="western"><surname>Charles</surname><given-names>JE</given-names></name><name name-style="western"><surname>Costantine</surname><given-names>MM</given-names></name><name name-style="western"><surname>Saade</surname><given-names>G</given-names></name><name name-style="western"><surname>Rood</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Buprenorphine X-waiver exemption - beyond the basics for the obstetrical provider</article-title>. <source>Am J Obstet Gynecol MFM</source>. (<year>2021</year>) <volume>3</volume>(<issue>6</issue>):<fpage>100451</fpage>. <pub-id pub-id-type="doi">10.1016/j.ajogmf.2021.100451</pub-id><pub-id pub-id-type="pmid">34320429</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loyal</surname><given-names>J</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>VN</given-names></name><name name-style="western"><surname>Picagli</surname><given-names>D</given-names></name><name name-style="western"><surname>Petrucelli</surname><given-names>A</given-names></name><name name-style="western"><surname>O'Mara</surname><given-names>E</given-names></name><name name-style="western"><surname>Grossman</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Postpartum nurses&#8217; experience caring for infants with neonatal abstinence syndrome</article-title>. <source>Hosp Pediatr</source>. (<year>2019</year>) <volume>9</volume>(<issue>8</issue>):<fpage>601</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1542/hpeds.2019-0087</pub-id><pub-id pub-id-type="pmid">31331933</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zedler</surname><given-names>BK</given-names></name><name name-style="western"><surname>Mann</surname><given-names>AL</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MM</given-names></name><name name-style="western"><surname>Amick</surname><given-names>HR</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>AR</given-names></name><name name-style="western"><surname>Murrelle</surname><given-names>L</given-names></name><etal/></person-group><article-title>Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child</article-title>. <source>Addiction</source>. (<year>2016</year>) <volume>111</volume>(<issue>12</issue>):<fpage>2115</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1111/add.13462</pub-id><pub-id pub-id-type="pmid">27223595</pub-id><pub-id pub-id-type="pmcid">PMC5129590</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiff</surname><given-names>DM</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>T</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Hood</surname><given-names>M</given-names></name><name name-style="western"><surname>Bernson</surname><given-names>D</given-names></name><name name-style="western"><surname>Diop</surname><given-names>H</given-names></name><etal/></person-group><article-title>Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts</article-title>. <source>Obstet Gynecol</source>. (<year>2018</year>) <volume>132</volume>(<issue>2</issue>):<fpage>466</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000002734</pub-id><pub-id pub-id-type="pmid">29995730</pub-id><pub-id pub-id-type="pmcid">PMC6060005</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>JR</given-names></name><name name-style="western"><surname>Schackman</surname><given-names>BR</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>ZM</given-names></name><name name-style="western"><surname>Walley</surname><given-names>AY</given-names></name><name name-style="western"><surname>Linas</surname><given-names>BP</given-names></name></person-group>. <article-title>Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort</article-title>. <source>Drug Alcohol Depend</source>. (<year>2019</year>) <volume>200</volume>:<fpage>34</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2019.02.031</pub-id><pub-id pub-id-type="pmid">31082666</pub-id><pub-id pub-id-type="pmcid">PMC6613830</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winhusen</surname><given-names>T</given-names></name><name name-style="western"><surname>Lofwall</surname><given-names>M</given-names></name><name name-style="western"><surname>Jones</surname><given-names>HE</given-names></name><name name-style="western"><surname>Wilder</surname><given-names>C</given-names></name><name name-style="western"><surname>Lindblad</surname><given-names>R</given-names></name><name name-style="western"><surname>Schiff</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Medication treatment for opioid use disorder in expectant mothers (MOMs): design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations</article-title>. <source>Contemp Clin Trials</source>. (<year>2020</year>) <volume>93</volume>:<fpage>106014</fpage>. <pub-id pub-id-type="doi">10.1016/j.cct.2020.106014</pub-id><pub-id pub-id-type="pmid">32353544</pub-id><pub-id pub-id-type="pmcid">PMC7184985</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Laird</surname><given-names>H</given-names></name><name name-style="western"><surname>Hand</surname><given-names>D</given-names></name><name name-style="western"><surname>Wright</surname><given-names>TE</given-names></name><name name-style="western"><surname>Premkumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Martin</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Opioid detoxification during pregnancy: a systematic review</article-title>. <source>Obstet Gynecol</source>. (<year>2018</year>) <volume>131</volume>(<issue>5</issue>):<fpage>803</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000002562</pub-id><pub-id pub-id-type="pmid">29630016</pub-id><pub-id pub-id-type="pmcid">PMC6034119</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>HE</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>M</given-names></name></person-group>. <article-title>Medically assisted withdrawal (detoxification): considering the mother-infant dyad</article-title>. <source>J Addict Med</source>. (<year>2017</year>) <volume>11</volume>(<issue>2</issue>):<fpage>90</fpage>&#8211;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1097/ADM.0000000000000289</pub-id><pub-id pub-id-type="pmid">28079573</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Short</surname><given-names>VL</given-names></name><name name-style="western"><surname>Hand</surname><given-names>DJ</given-names></name><name name-style="western"><surname>MacAfee</surname><given-names>L</given-names></name><name name-style="western"><surname>Abatemarco</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name></person-group>. <article-title>Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States</article-title>. <source>J Subst Abuse Treat</source>. (<year>2018</year>) <volume>89</volume>:<fpage>67</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsat.2018.04.003</pub-id><pub-id pub-id-type="pmid">29706175</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCarthy</surname><given-names>JJ</given-names></name></person-group>. <article-title>Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study: Re Meyer, et al</article-title>. <source>J Addict Med</source>. (<year>2016</year>) <volume>10</volume>(<issue>2</issue>):<fpage>133</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1097/ADM.0000000000000183</pub-id><pub-id pub-id-type="pmid">26985649</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>K</given-names></name><name name-style="western"><surname>Saver</surname><given-names>B</given-names></name><name name-style="western"><surname>Scanlan</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gianutsos</surname><given-names>LP</given-names></name><name name-style="western"><surname>Bhakta</surname><given-names>Y</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>J</given-names></name><etal/></person-group><article-title>Does maternal buprenorphine dose affect severity or incidence of neonatal abstinence syndrome?</article-title><source>J Addict Med</source>. (<year>2018</year>) <volume>12</volume>(<issue>6</issue>):<fpage>435</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1097/ADM.0000000000000427</pub-id><pub-id pub-id-type="pmid">29905586</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>HE</given-names></name><name name-style="western"><surname>Kaltenbach</surname><given-names>K</given-names></name><name name-style="western"><surname>Heil</surname><given-names>SH</given-names></name><name name-style="western"><surname>Stine</surname><given-names>SM</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>MG</given-names></name><name name-style="western"><surname>Arria</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Neonatal abstinence syndrome after methadone or buprenorphine exposure</article-title>. <source>N Engl J Med</source>. (<year>2010</year>) <volume>363</volume>(<issue>24</issue>):<fpage>2320</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1005359</pub-id><pub-id pub-id-type="pmid">21142534</pub-id><pub-id pub-id-type="pmcid">PMC3073631</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dugosh</surname><given-names>K</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>A</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>B</given-names></name><name name-style="western"><surname>McLoyd</surname><given-names>K</given-names></name><name name-style="western"><surname>Keli</surname><given-names>JD</given-names></name><name name-style="western"><surname>Chalk</surname><given-names>M</given-names></name><etal/></person-group><article-title>A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction</article-title>. <source>J Addict Med</source>. (<year>2016</year>) <volume>10</volume>(<issue>2</issue>):<fpage>93</fpage>&#8211;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1097/ADM.0000000000000193</pub-id><pub-id pub-id-type="pmid">26808307</pub-id><pub-id pub-id-type="pmcid">PMC4795974</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Ramanadhan</surname><given-names>S</given-names></name><name name-style="western"><surname>Locke</surname><given-names>A</given-names></name><name name-style="western"><surname>Longinaker</surname><given-names>N</given-names></name><name name-style="western"><surname>Lui</surname><given-names>S</given-names></name></person-group>. <article-title>Psychosocial interventions for pregnant women in outpatient illicit drug treatment programs compared to other interventions</article-title>. <source>Cochrane Database Syst Rev</source>. (<year>2015</year>) <volume>4</volume>:<fpage>Cd006037</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD006037.pub3</pub-id><pub-id pub-id-type="pmcid">PMC4894519</pub-id><pub-id pub-id-type="pmid">25835053</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="book"><collab>National Academies of Sciences, Engineering, and Medicine</collab>. <source>Medications for opioid use disorder save lives</source>. <publisher-name>National Academies Press</publisher-name> (<year>2019</year>).<pub-id pub-id-type="pmid">30896911</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilder</surname><given-names>C</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>D</given-names></name><name name-style="western"><surname>Winhusen</surname><given-names>T</given-names></name></person-group>. <article-title>Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder</article-title>. <source>Drug Alcohol Depend</source>. (<year>2015</year>) <volume>149</volume>:<fpage>225</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.02.012</pub-id><pub-id pub-id-type="pmid">25735465</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleinman</surname><given-names>MB</given-names></name><name name-style="western"><surname>Felton</surname><given-names>JW</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>A</given-names></name><name name-style="western"><surname>Magidson</surname><given-names>JF</given-names></name></person-group>. <article-title>&#8220;I have to be around people that are doing what i'm doing&#8221;: the importance of expanding the peer recovery coach role in treatment of opioid use disorder in the face of COVID-19 health disparities</article-title>. <source>J Subst Abuse Treat</source>. (<year>2021</year>) <volume>122</volume>:<fpage>108182</fpage>. <pub-id pub-id-type="doi">10.1016/j.jsat.2020.108182</pub-id><pub-id pub-id-type="pmid">33160763</pub-id><pub-id pub-id-type="pmcid">PMC7577312</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fallin-Bennett</surname><given-names>A</given-names></name><name name-style="western"><surname>Elswick</surname><given-names>A</given-names></name><name name-style="western"><surname>Ashford</surname><given-names>K</given-names></name></person-group>. <article-title>Peer support specialists and perinatal opioid use disorder: someone that's been there, lived it, seen it</article-title>. <source>Addict Behav</source>. (<year>2020</year>) <volume>102</volume>:<fpage>106204</fpage>. <pub-id pub-id-type="doi">10.1016/j.addbeh.2019.106204</pub-id><pub-id pub-id-type="pmid">31794901</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blandthorn</surname><given-names>J</given-names></name><name name-style="western"><surname>Bowman</surname><given-names>E</given-names></name><name name-style="western"><surname>Leung</surname><given-names>L</given-names></name><name name-style="western"><surname>Bonomo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dietze</surname><given-names>P</given-names></name></person-group>. <article-title>Managing opioid overdose in pregnancy with take-home naloxone</article-title>. <source>Aust N Z J Obstet Gynaecol</source>. (<year>2018</year>) <volume>58</volume>(<issue>4</issue>):<fpage>460</fpage>&#8211;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1111/ajo.12761</pub-id><pub-id pub-id-type="pmid">29271100</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haffajee</surname><given-names>RL</given-names></name><name name-style="western"><surname>Cherney</surname><given-names>S</given-names></name><name name-style="western"><surname>Smart</surname><given-names>R</given-names></name></person-group>. <article-title>Legal requirements and recommendations to prescribe naloxone</article-title>. <source>Drug Alcohol Depend</source>. (<year>2020</year>) <volume>209</volume>:<fpage>107896</fpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2020.107896</pub-id><pub-id pub-id-type="pmid">32058248</pub-id><pub-id pub-id-type="pmcid">PMC7127952</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>May</surname><given-names>PA</given-names></name><name name-style="western"><surname>Baete</surname><given-names>A</given-names></name><name name-style="western"><surname>Russo</surname><given-names>J</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Blankenship</surname><given-names>J</given-names></name><name name-style="western"><surname>Kalberg</surname><given-names>WO</given-names></name><etal/></person-group><article-title>Prevalence and characteristics of fetal alcohol spectrum disorders</article-title>. <source>Pediatrics</source>. (<year>2014</year>) <volume>134</volume>(<issue>5</issue>):<fpage>855</fpage>&#8211;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2013-3319</pub-id><pub-id pub-id-type="pmid">25349310</pub-id><pub-id pub-id-type="pmcid">PMC4210790</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campos</surname><given-names>J</given-names></name><name name-style="western"><surname>Roca</surname><given-names>L</given-names></name><name name-style="western"><surname>Gude</surname><given-names>F</given-names></name><name name-style="western"><surname>Gonzalez-Quintela</surname><given-names>A</given-names></name></person-group>. <article-title>Long-term mortality of patients admitted to the hospital with alcohol withdrawal syndrome</article-title>. <source>Alcohol Clin Exp Res</source>. (<year>2011</year>) <volume>35</volume>(<issue>6</issue>):<fpage>1180</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1530-0277.2011.01451.x</pub-id><pub-id pub-id-type="pmid">21352245</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crotty</surname><given-names>K</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>KI</given-names></name><name name-style="western"><surname>Kampman</surname><given-names>KM</given-names></name></person-group>. <article-title>Executive summary of the focused update of the ASAM national practice guideline for the treatment of opioid use disorder</article-title>. <source>J Addict Med</source>. (<year>2020</year>) <volume>14</volume>(<issue>2</issue>):<fpage>99</fpage>&#8211;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1097/ADM.0000000000000635</pub-id><pub-id pub-id-type="pmid">32209915</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pettinati</surname><given-names>HM</given-names></name></person-group>. <article-title>A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence</article-title>. <source>J Stud Alcohol Suppl</source>. (<year>2005</year>) <volume>15</volume>:<fpage>170</fpage>&#8211;<lpage>8</lpage><comment>; discussion 168&#8211;9</comment>. <pub-id pub-id-type="doi">10.15288/jsas.2005.s15.170</pub-id><pub-id pub-id-type="pmid">16223068</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anton</surname><given-names>RF</given-names></name><name name-style="western"><surname>O'Malley</surname><given-names>SS</given-names></name><name name-style="western"><surname>Ciraulo</surname><given-names>DA</given-names></name><name name-style="western"><surname>Cisler</surname><given-names>RA</given-names></name><name name-style="western"><surname>Couper</surname><given-names>D</given-names></name><name name-style="western"><surname>Donovan</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial</article-title>. <source>J Am Med Assoc</source>. (<year>2006</year>) <volume>295</volume>(<issue>17</issue>):<fpage>2003</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1001/jama.295.17.2003</pub-id><pub-id pub-id-type="pmid">16670409</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Lui</surname><given-names>S</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name></person-group>. <article-title>Pharmacologic interventions for pregnant women enrolled in alcohol treatment</article-title>. <source>Cochrane Database Syst Rev</source>. (<year>2009</year>) <volume>2009</volume>(<issue>3</issue>):<fpage>Cd007361</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD007361.pub2</pub-id><pub-id pub-id-type="pmid">19588428</pub-id><pub-id pub-id-type="pmcid">PMC7208248</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelty</surname><given-names>E</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Greenland</surname><given-names>M</given-names></name><name name-style="western"><surname>Preen</surname><given-names>D</given-names></name></person-group>. <article-title>Pharmacotherapies for the treatment of alcohol use disorders during pregnancy: time to reconsider?</article-title><source>Drugs</source>. (<year>2021</year>) <volume>81</volume>(<issue>7</issue>):<fpage>739</fpage>&#8211;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1007/s40265-021-01509-x</pub-id><pub-id pub-id-type="pmid">33830479</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeVido</surname><given-names>J</given-names></name><name name-style="western"><surname>Bogunovic</surname><given-names>O</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>RD</given-names></name></person-group>. <article-title>Alcohol use disorders in pregnancy</article-title>. <source>Harv Rev Psychiatry</source>. (<year>2015</year>) <volume>23</volume>(<issue>2</issue>):<fpage>112</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1097/HRP.0000000000000070</pub-id><pub-id pub-id-type="pmid">25747924</pub-id><pub-id pub-id-type="pmcid">PMC4530607</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>VT</given-names></name><name name-style="western"><surname>Dietz</surname><given-names>PM</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>B</given-names></name><name name-style="western"><surname>D'Angelo</surname><given-names>DV</given-names></name><name name-style="western"><surname>Farr</surname><given-names>SL</given-names></name><name name-style="western"><surname>Rockhill</surname><given-names>KM</given-names></name></person-group>. <article-title>Trends in smoking before, during, and after pregnancy&#8211;pregnancy risk assessment monitoring system, United States, 40 sites, 2000-2010</article-title>. <source>MMWR Surveill Summ</source>. (<year>2013</year>) <volume>62</volume>(<issue>6</issue>):<fpage>1</fpage>&#8211;<lpage>19</lpage>. PMID: <pub-id pub-id-type="pmid">24196750</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Claire</surname><given-names>R</given-names></name><name name-style="western"><surname>Chamberlain</surname><given-names>C</given-names></name><name name-style="western"><surname>Davey</surname><given-names>MA</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>SE</given-names></name><name name-style="western"><surname>Berlin</surname><given-names>I</given-names></name><name name-style="western"><surname>Leonardi-Bee</surname><given-names>J</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>T</given-names></name></person-group>. <article-title>Pharmacological interventions for promoting smoking cessation during pregnancy</article-title>. <source>Cochrane Database Syst Rev</source>. (<year>2020</year>) <volume>3</volume>(<issue>3</issue>):<fpage>Cd010078</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD010078.pub3</pub-id><pub-id pub-id-type="pmid">32129504</pub-id><pub-id pub-id-type="pmcid">PMC7059898</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKee</surname><given-names>SE</given-names></name><name name-style="western"><surname>Smith</surname><given-names>PH</given-names></name><name name-style="western"><surname>Kaufman</surname><given-names>M</given-names></name><name name-style="western"><surname>Mazure</surname><given-names>CM</given-names></name><name name-style="western"><surname>Weinberger</surname><given-names>AH</given-names></name></person-group>. <article-title>Sex differences in varenicline efficacy for smoking cessation: a meta-analysis</article-title>. <source>Nicotine Tob Res</source>. (<year>2016</year>) <volume>18</volume>(<issue>5</issue>):<fpage>1002</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1093/ntr/ntv207</pub-id><pub-id pub-id-type="pmid">26446070</pub-id><pub-id pub-id-type="pmcid">PMC5942618</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coles</surname><given-names>CD</given-names></name></person-group>. <article-title>Saying &#8220;goodbye&#8221; to the &#8220;crack baby&#8221;</article-title>. <source>Neurotoxicol Teratol</source>. (<year>1993</year>) <volume>15</volume>(<issue>5</issue>):<fpage>290</fpage>&#8211;<lpage>2</lpage><comment>; discussion 311&#8211;2</comment>. <pub-id pub-id-type="doi">10.1016/0892-0362(93)90024-I</pub-id><pub-id pub-id-type="pmid">8277917</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metzl</surname><given-names>JM</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>DE</given-names></name></person-group>. <article-title>Structural competency meets structural racism: race, politics, and the structure of medical knowledge</article-title>. <source>AMA J Ethics</source>. (<year>2014</year>) <volume>16</volume>(<issue>9</issue>):<fpage>674</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1001/virtualmentor.2014.16.9.spec1-1409</pub-id><pub-id pub-id-type="pmid">25216304</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frank</surname><given-names>DA</given-names></name><name name-style="western"><surname>Augustyn</surname><given-names>M</given-names></name><name name-style="western"><surname>Knight</surname><given-names>WG</given-names></name><name name-style="western"><surname>Pell</surname><given-names>T</given-names></name><name name-style="western"><surname>Zuckerman</surname><given-names>B</given-names></name></person-group>. <article-title>Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review</article-title>. <source>J Am Med Assoc</source>. (<year>2001</year>) <volume>285</volume>(<issue>12</issue>):<fpage>1613</fpage>&#8211;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1001/jama.285.12.1613</pub-id><pub-id pub-id-type="pmcid">PMC2504866</pub-id><pub-id pub-id-type="pmid">11268270</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>TR</given-names></name><name name-style="western"><surname>Sorg</surname><given-names>J</given-names></name><name name-style="western"><surname>Miller</surname><given-names>L</given-names></name><name name-style="western"><surname>Key</surname><given-names>TC</given-names></name><name name-style="western"><surname>Resnik</surname><given-names>R</given-names></name></person-group>. <article-title>Hemodynamic effects of intravenous cocaine on the pregnant ewe and fetus</article-title>. <source>Am J Obstet Gynecol</source>. (<year>1986</year>) <volume>155</volume>(<issue>4</issue>):<fpage>883</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9378(86)80044-8</pub-id><pub-id pub-id-type="pmid">3766645</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>B</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>K</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>M</given-names></name><name name-style="western"><surname>Ayers</surname><given-names>C</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>J</given-names></name><name name-style="western"><surname>Kansagara</surname><given-names>D</given-names></name></person-group>. <article-title>Pharmacotherapy for cocaine use disorder-a systematic review and meta-analysis</article-title>. <source>J Gen Intern Med</source>. (<year>2019</year>) <volume>34</volume>(<issue>12</issue>):<fpage>2858</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1007/s11606-019-05074-8</pub-id><pub-id pub-id-type="pmid">31183685</pub-id><pub-id pub-id-type="pmcid">PMC6854210</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smid</surname><given-names>MC</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name></person-group>. <article-title>What obstetrician-gynecologists should know about substance use disorders in the perinatal period</article-title>. <source>Obstet Gynecol</source>. (<year>2022</year>) <volume>139</volume>(<issue>2</issue>):<fpage>317</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000004657</pub-id><pub-id pub-id-type="pmid">34991147</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>D</given-names></name><name name-style="western"><surname>Kenneally</surname><given-names>M</given-names></name><name name-style="western"><surname>Van DenHeuvel</surname><given-names>C</given-names></name><name name-style="western"><surname>Byard</surname><given-names>RW</given-names></name></person-group>. <article-title>Methamphetamine deaths: changing trends and diagnostic issues</article-title>. <source>Med Sci Law</source>. (<year>2021</year>) <volume>61</volume>(<issue>2</issue>):<fpage>130</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1177/0025802420986707</pub-id><pub-id pub-id-type="pmid">33423599</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenkins</surname><given-names>RA</given-names></name><name name-style="western"><surname>Whitney</surname><given-names>BM</given-names></name><name name-style="western"><surname>Nance</surname><given-names>RM</given-names></name><name name-style="western"><surname>Allen</surname><given-names>TM</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>HLF</given-names></name><name name-style="western"><surname>Feinberg</surname><given-names>J</given-names></name><etal/></person-group><article-title>The rural opioid initiative consortium description: providing evidence to understand the fourth wave of the opioid crisis</article-title>. <source>Addict Sci Clin Pract</source>. (<year>2022</year>) <volume>17</volume>(<issue>1</issue>):<fpage>38</fpage>. <pub-id pub-id-type="doi">10.1186/s13722-022-00322-5</pub-id><pub-id pub-id-type="pmid">35883197</pub-id><pub-id pub-id-type="pmcid">PMC9321271</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>LM</given-names></name><name name-style="western"><surname>LaGasse</surname><given-names>LL</given-names></name><name name-style="western"><surname>Derauf</surname><given-names>C</given-names></name><name name-style="western"><surname>Grant</surname><given-names>P</given-names></name><name name-style="western"><surname>Shah</surname><given-names>R</given-names></name><name name-style="western"><surname>Arria</surname><given-names>A</given-names></name><etal/></person-group><article-title>The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth</article-title>. <source>Pediatrics</source>. (<year>2006</year>) <volume>118</volume>(<issue>3</issue>):<fpage>1149</fpage>&#8211;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2005-2564</pub-id><pub-id pub-id-type="pmid">16951010</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiblawi</surname><given-names>ZN</given-names></name><name name-style="western"><surname>Smith</surname><given-names>LM</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>SD</given-names></name><name name-style="western"><surname>LaGasse</surname><given-names>LL</given-names></name><name name-style="western"><surname>Derauf</surname><given-names>C</given-names></name><name name-style="western"><surname>Newman</surname><given-names>E</given-names></name><etal/></person-group><article-title>Prenatal methamphetamine exposure and neonatal and infant neurobehavioral outcome: results from the IDEAL study</article-title>. <source>Subst Abus</source>. (<year>2014</year>) <volume>35</volume>(<issue>1</issue>):<fpage>68</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1080/08897077.2013.814614</pub-id><pub-id pub-id-type="pmid">24588296</pub-id><pub-id pub-id-type="pmcid">PMC3942806</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>LM</given-names></name><name name-style="western"><surname>LaGasse</surname><given-names>LL</given-names></name><name name-style="western"><surname>Derauf</surname><given-names>C</given-names></name><name name-style="western"><surname>Grant</surname><given-names>P</given-names></name><name name-style="western"><surname>Shah</surname><given-names>R</given-names></name><name name-style="western"><surname>Arria</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prenatal methamphetamine use and neonatal neurobehavioral outcome</article-title>. <source>Neurotoxicol Teratol</source>. (<year>2008</year>) <volume>30</volume>(<issue>1</issue>):<fpage>20</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ntt.2007.09.005</pub-id><pub-id pub-id-type="pmid">18031987</pub-id><pub-id pub-id-type="pmcid">PMC2358984</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siefried</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Acheson</surname><given-names>LS</given-names></name><name name-style="western"><surname>Lintzeris</surname><given-names>N</given-names></name><name name-style="western"><surname>Ezard</surname><given-names>N</given-names></name></person-group>. <article-title>Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review</article-title>. <source>CNS Drugs</source>. (<year>2020</year>) <volume>34</volume>(<issue>4</issue>):<fpage>337</fpage>&#8211;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1007/s40263-020-00711-x</pub-id><pub-id pub-id-type="pmid">32185696</pub-id><pub-id pub-id-type="pmcid">PMC7125061</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naji</surname><given-names>L</given-names></name><name name-style="western"><surname>Dennis</surname><given-names>B</given-names></name><name name-style="western"><surname>Rosic</surname><given-names>T</given-names></name><name name-style="western"><surname>Wiercioch</surname><given-names>W</given-names></name><name name-style="western"><surname>Paul</surname><given-names>J</given-names></name><name name-style="western"><surname>Worster</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: a systematic review and meta-analysis</article-title>. <source>Drug Alcohol Depend</source>. (<year>2022</year>) <volume>232</volume>:<fpage>109295</fpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2022.109295</pub-id><pub-id pub-id-type="pmid">35066460</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takeshima</surname><given-names>N</given-names></name><name name-style="western"><surname>Hayasaka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tajika</surname><given-names>A</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>N</given-names></name><name name-style="western"><surname>Streiner</surname><given-names>D</given-names></name><name name-style="western"><surname>Furukawa</surname><given-names>TA</given-names></name></person-group>. <article-title>Antidepressants plus benzodiazepines for adults with major depression</article-title>. <source>Cochrane Database Syst Rev</source>. (<year>2019</year>) <volume>6</volume>(<issue>6</issue>):<fpage>Cd001026</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD001026.pub2</pub-id><pub-id pub-id-type="pmid">31158298</pub-id><pub-id pub-id-type="pmcid">PMC6546439</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>E</given-names></name><name name-style="western"><surname>Goldner</surname><given-names>EM</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>B</given-names></name></person-group>. <article-title>Benzodiazepine use, misuse, and harm at the population level in Canada: a comprehensive narrative review of data and developments since 1995</article-title>. <source>Clin Drug Investig</source>. (<year>2016</year>) <volume>36</volume>(<issue>7</issue>):<fpage>519</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1007/s40261-016-0397-8</pub-id><pub-id pub-id-type="pmid">27056579</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez</surname><given-names>I</given-names></name><name name-style="western"><surname>He</surname><given-names>M</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>MM</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group>. <article-title>Exposure-response association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in medicare part D beneficiaries</article-title>. <source>JAMA Netw Open</source>. (<year>2018</year>) <volume>1</volume>(<issue>2</issue>):<fpage>e180919</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2018.0919</pub-id><pub-id pub-id-type="pmid">30646080</pub-id><pub-id pub-id-type="pmcid">PMC6324417</pub-id></mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venkatesh</surname><given-names>KK</given-names></name><name name-style="western"><surname>Pate</surname><given-names>V</given-names></name><name name-style="western"><surname>Boggess</surname><given-names>KA</given-names></name><name name-style="western"><surname>Jones</surname><given-names>HE</given-names></name><name name-style="western"><surname>Jonsson Funk</surname><given-names>M</given-names></name><name name-style="western"><surname>Smid</surname><given-names>MC</given-names></name></person-group>. <article-title>Trends in opioid and psychotropic prescription in pregnancy in the United States from 2001 to 2015 in a privately insured population: a cross-sectional study</article-title>. <source>Ann Intern Med</source>. (<year>2020</year>) <volume>173</volume>(<issue>11 Suppl</issue>):<fpage>S19</fpage>&#8211;<lpage>s28</lpage>. <pub-id pub-id-type="doi">10.7326/M19-3249</pub-id><pub-id pub-id-type="pmid">33253018</pub-id></mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bais</surname><given-names>B</given-names></name><name name-style="western"><surname>Molenaar</surname><given-names>NM</given-names></name><name name-style="western"><surname>Bijma</surname><given-names>HH</given-names></name><name name-style="western"><surname>Hoogendijk</surname><given-names>WJG</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>CL</given-names></name><name name-style="western"><surname>Luik</surname><given-names>AI</given-names></name><etal/></person-group><article-title>Prevalence of benzodiazepines and benzodiazepine-related drugs exposure before, during and after pregnancy: a systematic review and meta-analysis</article-title>. <source>J Affect Disord</source>. (<year>2020</year>) <volume>269</volume>:<fpage>18</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2020.03.014</pub-id><pub-id pub-id-type="pmid">32217339</pub-id></mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>TW</given-names></name><name name-style="western"><surname>Larochelle</surname><given-names>MR</given-names></name><name name-style="western"><surname>Saitz</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Bernson</surname><given-names>D</given-names></name><name name-style="western"><surname>Walley</surname><given-names>AY</given-names></name></person-group>. <article-title>Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine</article-title>. <source>Addiction</source>. (<year>2020</year>) <volume>115</volume>(<issue>5</issue>):<fpage>924</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1111/add.14886</pub-id><pub-id pub-id-type="pmid">31916306</pub-id><pub-id pub-id-type="pmcid">PMC7156323</pub-id></mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grigoriadis</surname><given-names>S</given-names></name><name name-style="western"><surname>Graves</surname><given-names>L</given-names></name><name name-style="western"><surname>Peer</surname><given-names>M</given-names></name><name name-style="western"><surname>Mamisashvili</surname><given-names>L</given-names></name><name name-style="western"><surname>Dennis</surname><given-names>C-L</given-names></name><name name-style="western"><surname>Vigod</surname><given-names>SN</given-names></name><etal/></person-group><article-title>Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta-analysis</article-title>. <source>J Clin Psychiatry</source>. (<year>2019</year>) <volume>80</volume>(<issue>4</issue>):<fpage>18r12412</fpage>. <pub-id pub-id-type="doi">10.4088/JCP.18r12412</pub-id><pub-id pub-id-type="pmid">31294935</pub-id></mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rementer&#237;a</surname><given-names>JL</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>K</given-names></name></person-group>. <article-title>Withdrawal symptoms in neonates from intrauterine exposure to diazepam</article-title>. <source>J Pediatr</source>. (<year>1977</year>) <volume>90</volume>(<issue>1</issue>):<fpage>123</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-3476(77)80785-3</pub-id><pub-id pub-id-type="pmid">830876</pub-id></mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seligman</surname><given-names>NS</given-names></name><name name-style="western"><surname>Salva</surname><given-names>N</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Dysart</surname><given-names>KC</given-names></name><name name-style="western"><surname>Pequignot</surname><given-names>EC</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>JK</given-names></name></person-group>. <article-title>Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates</article-title>. <source>Am J Obstet Gynecol</source>. (<year>2008</year>) <volume>199</volume>(<issue>4</issue>):<fpage>396</fpage>. <pub-id pub-id-type="doi">10.1016/j.ajog.2008.06.088</pub-id><pub-id pub-id-type="pmid">18928986</pub-id></mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voshaar</surname><given-names>RCO</given-names></name><name name-style="western"><surname>Couvee</surname><given-names>JE</given-names></name><name name-style="western"><surname>Van Balkom</surname><given-names>AJLM</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>PGH</given-names></name><name name-style="western"><surname>Zitman</surname><given-names>FG</given-names></name></person-group>. <article-title>Strategies for discontinuing long-term benzodiazepine use: meta-analysis</article-title>. <source>Br J Psychiatry</source>. (<year>2006</year>) <volume>189</volume>:<fpage>213</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1192/bjp.189.3.213</pub-id><pub-id pub-id-type="pmid">16946355</pub-id></mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>JC</given-names></name><name name-style="western"><surname>Tarr</surname><given-names>JA</given-names></name><name name-style="western"><surname>Holland</surname><given-names>CL</given-names></name><name name-style="western"><surname>De Genna</surname><given-names>NM</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>GE</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Beliefs and attitudes regarding prenatal marijuana use: perspectives of pregnant women who report use</article-title>. <source>Drug Alcohol Depend</source>. (<year>2019</year>) <volume>196</volume>:<fpage>14</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.11.028</pub-id><pub-id pub-id-type="pmid">30658220</pub-id><pub-id pub-id-type="pmcid">PMC6756431</pub-id></mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young-Wolff</surname><given-names>KC</given-names></name><name name-style="western"><surname>Sarovar</surname><given-names>V</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>LY</given-names></name><name name-style="western"><surname>Avalos</surname><given-names>LA</given-names></name><name name-style="western"><surname>Alexeeff</surname><given-names>S</given-names></name><name name-style="western"><surname>Conway</surname><given-names>A</given-names></name><etal/></person-group><article-title>Trends in marijuana use among pregnant women with and without nausea and vomiting in pregnancy, 2009-2016</article-title>. <source>Drug Alcohol Depend</source>. (<year>2019</year>) <volume>196</volume>:<fpage>66</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.12.009</pub-id><pub-id pub-id-type="pmid">30711893</pub-id><pub-id pub-id-type="pmcid">PMC6392046</pub-id></mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlier</surname><given-names>J</given-names></name><name name-style="western"><surname>Huestis</surname><given-names>MA</given-names></name><name name-style="western"><surname>Zaami</surname><given-names>S</given-names></name><name name-style="western"><surname>Pichini</surname><given-names>S</given-names></name><name name-style="western"><surname>Busardo</surname><given-names>FP</given-names></name></person-group>. <article-title>Monitoring perinatal exposure to cannabis and synthetic cannabinoids</article-title>. <source>Ther Drug Monit</source>. (<year>2020</year>) <volume>42</volume>(<issue>2</issue>):<fpage>194</fpage>&#8211;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1097/FTD.0000000000000667</pub-id><pub-id pub-id-type="pmid">32195988</pub-id></mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>K</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>A</given-names></name></person-group>. <article-title>The effects of cannabinoids on executive functions: evidence from Cannabis and synthetic cannabinoids-A systematic review</article-title>. <source>Brain Sci</source>. (<year>2018</year>) <volume>8</volume>(<issue>3</issue>):<fpage>133</fpage>. <pub-id pub-id-type="doi">10.3390/brainsci8030040</pub-id><pub-id pub-id-type="pmid">29495540</pub-id><pub-id pub-id-type="pmcid">PMC5870358</pub-id></mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>SA</given-names></name><name name-style="western"><surname>Ammerman</surname><given-names>SD</given-names></name><name name-style="western"><surname>O'Connor</surname><given-names>ME</given-names></name></person-group>, <collab>AAP Committee on Substance Use and Prevention</collab>, <collab>AAP Section on Breastfeeding</collab>. <article-title>Marijuana use during pregnancy and breastfeeding: implications for neonatal and childhood outcomes</article-title>. <source>Pediatrics</source>. (<year>2018</year>) <volume>142</volume>(<issue>3</issue>):<fpage>e20181889</fpage>. <pub-id pub-id-type="doi">10.1542/peds.2018-1889</pub-id><pub-id pub-id-type="pmid">30150209</pub-id></mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kondo</surname><given-names>KK</given-names></name><etal/></person-group><article-title>Pharmacotherapy for the treatment of Cannabis use disorder: a systematic review</article-title>. <source>Ann Intern Med</source>. (<year>2020</year>) <volume>172</volume>(<issue>6</issue>):<fpage>398</fpage>&#8211;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.7326/M19-1105</pub-id><pub-id pub-id-type="pmid">32120384</pub-id></mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kondo</surname><given-names>KK</given-names></name><name name-style="western"><surname>Morasco</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Nugent</surname><given-names>SM</given-names></name><name name-style="western"><surname>Ayers</surname><given-names>CK</given-names></name><name name-style="western"><surname>O'Neil</surname><given-names>ME</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Treating perioperative and acute pain in patients on buprenorphine: narrative literature review and practice recommendations</article-title>. <source>J Gen Intern Med</source>. (<year>2020</year>) <volume>35</volume>(<issue>12</issue>):<fpage>3635</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1007/s11606-020-06115-3</pub-id><pub-id pub-id-type="pmid">32827109</pub-id><pub-id pub-id-type="pmcid">PMC7728902</pub-id></mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buresh</surname><given-names>M</given-names></name><name name-style="western"><surname>Ratner</surname><given-names>J</given-names></name><name name-style="western"><surname>Zgierska</surname><given-names>A</given-names></name><name name-style="western"><surname>Gordin</surname><given-names>V</given-names></name><name name-style="western"><surname>Alvanzo</surname><given-names>A</given-names></name></person-group>. <article-title>Managing acute pain in patients taking medication for opioid use disorder: a rapid review</article-title>. <source>J Gen Intern Med</source>. (<year>2020</year>) <volume>35</volume>(<issue>Suppl 3</issue>):<fpage>945</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1007/s11606-020-06256-5</pub-id><pub-id pub-id-type="pmid">33145688</pub-id><pub-id pub-id-type="pmcid">PMC7728869</pub-id></mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veazie</surname><given-names>S</given-names></name><name name-style="western"><surname>Mackey</surname><given-names>K</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>K</given-names></name><name name-style="western"><surname>Bourne</surname><given-names>D</given-names></name></person-group>. <article-title>National partnership for maternal safety: consensus bundle on obstetric care for women with opioid use disorder</article-title>. <source>Obstet Gynecol</source>. (<year>2019</year>) <volume>134</volume>(<issue>2</issue>):<fpage>365</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000003381</pub-id><pub-id pub-id-type="pmid">31306323</pub-id></mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Krans</surname><given-names>EE</given-names></name><name name-style="western"><surname>Campopiano</surname><given-names>M</given-names></name><name name-style="western"><surname>Cleveland</surname><given-names>L</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>D</given-names></name><name name-style="western"><surname>Kilday</surname><given-names>D</given-names></name><name name-style="western"><surname>Kendig</surname><given-names>SJD</given-names></name><etal/></person-group><comment>Care for pregnant and postpartum people with substance use disorder (2021). Available at:</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://saferbirth.org/psbs/care-for-pregnant-and-postpartum-people-with-substance-use-disorder/" ext-link-type="uri">https://saferbirth.org/psbs/care-for-pregnant-and-postpartum-people-with-substance-use-disorder/</ext-link><comment>(Accessed September 15, 2022)</comment>.</mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation publication-type="journal"><collab>Association of women&#8217;s health, obstetric and neonatal nurses</collab>. <article-title>Breastfeeding and the use of human milk</article-title>. <source>Pediatrics</source>. (<year>2012</year>) <volume>129</volume>(<issue>3</issue>):<fpage>e827</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2011-3552</pub-id><pub-id pub-id-type="pmid">22371471</pub-id></mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grywacheski</surname><given-names>V</given-names></name><etal/></person-group><article-title>Opioid and Cannabis use during pregnancy and breastfeeding in relation to sociodemographics and mental health status: a descriptive study</article-title>. <source>J Obstet Gynaecol Can</source>. (<year>2021</year>) <volume>43</volume>(<issue>3</issue>):<fpage>329</fpage>&#8211;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.jogc.2020.09.017</pub-id><pub-id pub-id-type="pmid">33229280</pub-id></mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grywacheski</surname><given-names>V</given-names></name><name name-style="western"><surname>Ali</surname><given-names>J</given-names></name><name name-style="western"><surname>Baker</surname><given-names>MM</given-names></name><name name-style="western"><surname>Gheorghe</surname><given-names>M</given-names></name><name name-style="western"><surname>Wong</surname><given-names>SL</given-names></name><name name-style="western"><surname>Orpana</surname><given-names>HM</given-names></name></person-group>. <article-title>Test or talk: empiric bias and epistemic injustice</article-title>. <source>Obstet Gynecol</source>. (<year>2022</year>) <volume>140</volume>(<issue>2</issue>):<fpage>150</fpage>&#8211;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000004884</pub-id><pub-id pub-id-type="pmid">35852262</pub-id></mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benitz</surname><given-names>WE</given-names></name><etal/></person-group><article-title>Hospital stay for healthy term newborn infants</article-title>. <source>Pediatrics</source>. (<year>2015</year>) <volume>135</volume>(<issue>5</issue>):<fpage>948</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2015-0699</pub-id><pub-id pub-id-type="pmid">25917993</pub-id></mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benitz</surname><given-names>WE</given-names></name><name name-style="western"><surname>Aucott</surname><given-names>S</given-names></name><name name-style="western"><surname>Benitz</surname><given-names>WE</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Eichenwald</surname><given-names>EC</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>J</given-names></name><etal/></person-group><article-title>Standardizing the clinical definition of opioid withdrawal in the neonate</article-title>. <source>J Pediatr</source>. (<year>2022</year>) <volume>243</volume>:<fpage>33</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpeds.2021.12.021</pub-id><pub-id pub-id-type="pmid">34942181</pub-id></mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Jilani</surname><given-names>SM</given-names></name><name name-style="western"><surname>Jones</surname><given-names>HE</given-names></name><name name-style="western"><surname>Grossman</surname><given-names>M</given-names></name><name name-style="western"><surname>Jansson</surname><given-names>LM</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Faherty</surname><given-names>LJ</given-names></name><etal/></person-group><comment>Opposition to criminalization of individuals during pregnancy and the postpartum period (2020)</comment>.</mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suomi</surname><given-names>A</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>A</given-names></name><name name-style="western"><surname>Pasalich</surname><given-names>D</given-names></name></person-group>. <article-title>The prevalence of post-traumatic stress disorder in birth parents in child protection services: systematic review and meta-analysis</article-title>. <source>Trauma Violence Abuse</source>. (<year>2021</year>) <volume>24</volume>(<issue>2</issue>):<fpage>1032</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1177/15248380211048444</pub-id><pub-id pub-id-type="pmid">34736361</pub-id></mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Sangoi</surname><given-names>L</given-names></name></person-group>. <comment>Whatever they do, I'm her comfort, I'm her protector. How the foster system has become ground zero for the US drug war. Movement for family power (2020)</comment>.</mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meinhofer</surname><given-names>A</given-names></name><name name-style="western"><surname>Angler&#243;-D&#237;az</surname><given-names>Y</given-names></name></person-group>. <article-title>Trends in foster care entry among children removed from their homes because of parental drug use, 2000 to 2017</article-title>. <source>JAMA Pediatr</source>. (<year>2019</year>) <volume>173</volume>(<issue>9</issue>):<fpage>881</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1001/jamapediatrics.2019.1738</pub-id><pub-id pub-id-type="pmid">31305925</pub-id><pub-id pub-id-type="pmcid">PMC6632152</pub-id></mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Admon</surname><given-names>LK</given-names></name><name name-style="western"><surname>Zivin</surname><given-names>K</given-names></name><name name-style="western"><surname>Kozhimannil</surname><given-names>KB</given-names></name></person-group>. <article-title>Perinatal insurance coverage and behavioural health-related maternal mortality</article-title>. <source>Int Rev Psychiatry</source>. (<year>2021</year>) <volume>33</volume>(<issue>6</issue>):<fpage>553</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1080/09540261.2021.1903843</pub-id><pub-id pub-id-type="pmid">34098849</pub-id><pub-id pub-id-type="pmcid">PMC9007041</pub-id></mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacDorman</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Causes contributing to the excess maternal mortality risk for women 35 and over, United States, 2016-2017</article-title>. <source>PLoS One</source>. (<year>2021</year>) <volume>16</volume>(<issue>6</issue>):<fpage>e0253920</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0253920</pub-id><pub-id pub-id-type="pmid">34185810</pub-id><pub-id pub-id-type="pmcid">PMC8241083</pub-id></mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacDorman</surname><given-names>MF</given-names></name><name name-style="western"><surname>Thorma</surname><given-names>M</given-names></name><name name-style="western"><surname>Declercq</surname><given-names>E</given-names></name><name name-style="western"><surname>Howell</surname><given-names>EA</given-names></name></person-group>. <article-title>Early lessons from maternal mortality review committees on drug-related deaths-time for obstetrical providers to take the lead in addressing addiction</article-title>. <source>Am J Obstet Gynecol MFM</source>. (<year>2020</year>) <volume>2</volume>(<issue>4</issue>):<fpage>100177</fpage>. <pub-id pub-id-type="doi">10.1016/j.ajogmf.2020.100177</pub-id><pub-id pub-id-type="pmid">33345905</pub-id><pub-id pub-id-type="pmcid">PMC7753059</pub-id></mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smid</surname><given-names>MC</given-names></name><name name-style="western"><surname>Schauberger</surname><given-names>CW</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Wright</surname><given-names>TE</given-names></name></person-group>. <article-title>Recent increases in the U.S. maternal mortality rate: disentangling trends from measurement issues</article-title>. <source>Obstet Gynecol</source>. (<year>2016</year>) <volume>128</volume>(<issue>3</issue>):<fpage>447</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000001556</pub-id><pub-id pub-id-type="pmid">27500333</pub-id><pub-id pub-id-type="pmcid">PMC5001799</pub-id></mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grigoriadis</surname><given-names>S</given-names></name><etal/></person-group><article-title>Perinatal suicide in Ontario, Canada: a 15-year population-based study</article-title>. <source>Can Med Assoc J</source>. (<year>2017</year>) <volume>189</volume>(<issue>34</issue>):<fpage>E1085</fpage>&#8211;<lpage>e1092</lpage>. <pub-id pub-id-type="doi">10.1503/cmaj.170088</pub-id><pub-id pub-id-type="pmid">28847780</pub-id><pub-id pub-id-type="pmcid">PMC5573543</pub-id></mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grigoriadis</surname><given-names>S</given-names></name><name name-style="western"><surname>Wilton</surname><given-names>AE</given-names></name><name name-style="western"><surname>Kurdyak</surname><given-names>PA</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>AE</given-names></name><name name-style="western"><surname>VonderPorten</surname><given-names>EH</given-names></name><name name-style="western"><surname>Levitt</surname><given-names>A</given-names></name><etal/></person-group><article-title>Associations between substance use disorders and suicide or suicide attempts in people with mental illness: a danish nation-wide, prospective, register-based study of patients diagnosed with schizophrenia, bipolar disorder, unipolar depression or personality disorder</article-title>. <source>Addiction</source>. (<year>2017</year>) <volume>112</volume>(<issue>7</issue>):<fpage>1250</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/add.13788</pub-id><pub-id pub-id-type="pmid">28192643</pub-id></mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forray</surname><given-names>A</given-names></name><name name-style="western"><surname>Yonkers</surname><given-names>KA</given-names></name></person-group>. <article-title>The collision of mental health, substance use disorder, and suicide</article-title>. <source>Obstet Gynecol</source>. (<year>2021</year>) <volume>137</volume>(<issue>6</issue>):<fpage>1083</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000004391</pub-id><pub-id pub-id-type="pmid">33957654</pub-id></mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation publication-type="journal"><collab>American College of Obstetricians and Gynecologists</collab>. <article-title>Committee opinion no. 757: screening for perinatal depression</article-title>. <source>Obstet Gynecol</source>. (<year>2018</year>) <volume>132</volume>(<issue>5</issue>):<fpage>e208</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000002927</pub-id><pub-id pub-id-type="pmid">30629567</pub-id></mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation publication-type="journal"><article-title>ACOG Committee opinion No. 736 summary: optimizing postpartum care</article-title>. <source>Obstet Gynecol</source>. (<year>2018</year>) <volume>131</volume>(<issue>5</issue>):<fpage>949</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000002628</pub-id><pub-id pub-id-type="pmid">29683906</pub-id></mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martino</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Exploring the link between substance use and abortion: the roles of unconventionality and unplanned pregnancy</article-title>. <source>Perspect Sex Reprod Health</source>. (<year>2006</year>) <volume>38</volume>(<issue>2</issue>):<fpage>66</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1363/3806606</pub-id><pub-id pub-id-type="pmid">16772187</pub-id></mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martino</surname><given-names>SC</given-names></name><name name-style="western"><surname>Collins</surname><given-names>RL</given-names></name><name name-style="western"><surname>Ellickson</surname><given-names>PL</given-names></name><name name-style="western"><surname>Klein</surname><given-names>DJ</given-names></name></person-group>. <article-title>The prevalence of unplanned pregnancy and associated factors in britain: findings from the third national survey of sexual attitudes and lifestyles (natsal-3)</article-title>. <source>Lancet</source>. (<year>2013</year>) <volume>382</volume>(<issue>9907</issue>):<fpage>1807</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(13)62071-1</pub-id><pub-id pub-id-type="pmid">24286786</pub-id><pub-id pub-id-type="pmcid">PMC3898922</pub-id></mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wellings</surname><given-names>K</given-names></name><name name-style="western"><surname>Jones</surname><given-names>KG</given-names></name><name name-style="western"><surname>Mercer</surname><given-names>CH</given-names></name><name name-style="western"><surname>Tanton</surname><given-names>C</given-names></name><name name-style="western"><surname>Clifton</surname><given-names>S</given-names></name><name name-style="western"><surname>Datta</surname><given-names>J</given-names></name><etal/></person-group><article-title>Unintended pregnancy in opioid-abusing women</article-title>. <source>J Subst Abuse Treat</source>. (<year>2011</year>) <volume>40</volume>(<issue>2</issue>):<fpage>199</fpage>&#8211;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsat.2010.08.011</pub-id><pub-id pub-id-type="pmid">21036512</pub-id><pub-id pub-id-type="pmcid">PMC3052960</pub-id></mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heil</surname><given-names>SH</given-names></name><name name-style="western"><surname>Jones</surname><given-names>HE</given-names></name><name name-style="western"><surname>Arria</surname><given-names>A</given-names></name><name name-style="western"><surname>Kaltenbacj</surname><given-names>K</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>M</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>G</given-names></name><etal/></person-group><article-title>Contraceptive use and method choice among women with opioid and other substance use disorders: a systematic review</article-title>. <source>Prev Med</source>. (<year>2015</year>) <volume>80</volume>:<fpage>23</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.ypmed.2015.04.008</pub-id><pub-id pub-id-type="pmid">25900803</pub-id><pub-id pub-id-type="pmcid">PMC4842019</pub-id></mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terplan</surname><given-names>M</given-names></name><name name-style="western"><surname>Hand</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hutchinson</surname><given-names>M</given-names></name><name name-style="western"><surname>Salisbury-Afshar</surname><given-names>E</given-names></name><name name-style="western"><surname>Heil</surname><given-names>SH</given-names></name></person-group>. <article-title>Factors associated with contraceptive use among postpartum women with substance use disorder</article-title>. <source>Sex Reprod Healthc</source>. (<year>2022</year>) <volume>33</volume>:<fpage>100764</fpage>. <pub-id pub-id-type="doi">10.1016/j.srhc.2022.100764</pub-id><pub-id pub-id-type="pmid">36057204</pub-id></mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shelton</surname><given-names>D</given-names></name><name name-style="western"><surname>Ramage</surname><given-names>M</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>P</given-names></name><name name-style="western"><surname>Tak</surname><given-names>C</given-names></name></person-group>. <article-title>Hepatitis C virus infection among reproductive-aged women and children in the United States, 2006 to 2014</article-title>. <source>Ann Intern Med</source>. (<year>2017</year>) <volume>166</volume>(<issue>11</issue>):<fpage>775</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.7326/M16-2350</pub-id><pub-id pub-id-type="pmid">28492929</pub-id></mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Ly</surname><given-names>KN</given-names></name><name name-style="western"><surname>Jiles</surname><given-names>RB</given-names></name><name name-style="western"><surname>Teshale</surname><given-names>EH</given-names></name><name name-style="western"><surname>Foster</surname><given-names>MA</given-names></name><name name-style="western"><surname>Pesano</surname><given-names>RL</given-names></name><name name-style="western"><surname>Holmberg</surname><given-names>SD</given-names></name></person-group>. <comment>Routine hepatitis C virus screening in pregnant individuals</comment>.</mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faherty</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Association between punitive policies and neonatal abstinence syndrome among medicaid-insured infants in complex policy environments</article-title>. <source>Addiction</source>. (<year>2022</year>) <volume>117</volume>(<issue>1</issue>):<fpage>162</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1111/add.15602</pub-id><pub-id pub-id-type="pmid">34096671</pub-id><pub-id pub-id-type="pmcid">PMC8648865</pub-id></mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faherty</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Heins</surname><given-names>S</given-names></name><name name-style="western"><surname>Kranz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Patrick</surname><given-names>SW</given-names></name></person-group>. <article-title>Forty years of state alcohol and pregnancy policies in the USA: best practices for public health or efforts to restrict women's reproductive rights?</article-title><source>Alcohol Alcohol</source>. (<year>2017</year>) <volume>52</volume>(<issue>6</issue>):<fpage>715</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1093/alcalc/agx047</pub-id><pub-id pub-id-type="pmid">29016712</pub-id><pub-id pub-id-type="pmcid">PMC5860145</pub-id></mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>SCM</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S</given-names></name><name name-style="western"><surname>Treffers</surname><given-names>R</given-names></name><name name-style="western"><surname>Drabble</surname><given-names>L</given-names></name></person-group>. <article-title>Association between state-level criminal justice-focused prenatal substance use policies in the US and substance use-related foster care admissions and family reunification</article-title>. <source>JAMA Pediatr</source>. (<year>2020</year>) <volume>174</volume>(<issue>8</issue>):<fpage>782</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1001/jamapediatrics.2020.1027</pub-id><pub-id pub-id-type="pmid">32421179</pub-id><pub-id pub-id-type="pmcid">PMC7235916</pub-id></mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanmartin</surname><given-names>MX</given-names></name><name name-style="western"><surname>Ali</surname><given-names>MM</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>S</given-names></name><name name-style="western"><surname>Aktas</surname><given-names>A</given-names></name></person-group>. <article-title>The racial geography of child welfare</article-title>. <source>Child Welfare</source>. (<year>2008</year>) <volume>87</volume>(<issue>2</issue>):<fpage>125</fpage>&#8211;<lpage>50</lpage>. PMID: <pub-id pub-id-type="pmid">18972935</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>